HU000028261T2

(19) **HU**

(11) Lajstromszám: **E 028 261**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 08 005889**
(22) A bejelentés napja: **2008. 03. 27.**

(96) Az európai bejelentés bejelentési száma:
EP 20080005889
(97) Az európai bejelentés közzétételi adatai:
EP 2105501 A1 **2009. 09. 30.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2105501 B1 **2015. 10. 07.**

(51) Int. Cl.: ***C12N 9/16*** *(2006.01)*
A61K 39/00 *(2006.01)*
A61P 35/00 *(2006.01)*
C07K 7/06 *(2006.01)*
C07K 7/08 *(2006.01)*

(72) Feltaláló(k):
Emmerich, Niels, Chicago, IL 60657 (US)
SINGH, Harpreet, 81679 München (DE)
Schoor Oliver, 72070 Tübingen (DE)
HILF, Norbert, 72138 Kirchentellinsfurt (DE)
WEINSCHENK, Toni, 73773 Aichwald (DE)
Trautwein, Claudia, 42489 Wülfrath (DE)
Walter, Steffen, 72764 Reutlingen (DE)

(73) Jogosult(ak):
Immatics Biotechnologies GmbH, 72076 Tübingen (DE)

(74) Képviselő:
Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Újszerű immunterápia neuronális és agydaganatok ellen**

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 105 501 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
07.10.2015 Bulletin 2015/41

(21) Application number: **08005889.4**

(22) Date of filing: **27.03.2008**

(51) Int Cl.:
C12N 9/16 *(2006.01)* ***C07K 7/06*** *(2006.01)*
C07K 7/08 *(2006.01)* ***A61K 39/00*** *(2006.01)*
A61P 35/00 *(2006.01)*

(54) **Novel immunotherapy against neuronal and brain tumors**

Neuartige Immuntherapie gegen Nerven- und Hirntumore

Nouvelle immunothérapie pour le traitement de tumeurs neuronales et cérébrales

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(43) Date of publication of application:
30.09.2009 Bulletin 2009/40

(73) Proprietor: **Immatics Biotechnologies GmbH**
72076 Tübingen (DE)

(72) Inventors:
- **Emmerich, Niels**
  Chicago, IL 60657 (US)
- **Singh, Harpreet**
  81679 München (DE)
- **Schoor Oliver**
  72070 Tübingen (DE)
- **Hilf, Norbert**
  72138 Kirchentellinsfurt (DE)
- **Weinschenk, Toni**
  73773 Aichwald (DE)
- **Trautwein, Claudia**
  42489 Wülfrath (DE)
- **Walter, Steffen**
  72764 Reutlingen (DE)

(74) Representative: **Krauss, Jan**
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Patentanwälte Rechtsanwälte
Pettenkoferstrasse 20-22
80336 München (DE)

(56) References cited:
WO-A-00/75339 **WO-A-2005/116051**
WO-A2-2004/085461 **US-A1- 2002 146 370**
US-A1- 2003 118 585

- **MULHOLLAND PAUL J ET AL: "Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme." CELL CYCLE (GEORGETOWN, TEX.) APR 2006, vol. 5, no. 7, April 2006 (2006-04), pages 783-791, XP002484251 ISSN: 1551-4005**
- **DATABASE UniProt [Online] 1 June 2001 (2001-06-01), "Ptprz1 protein (Fragment)." XP002484252 retrieved from EBI accession no. UNIPROT:Q99LN6 Database accession no. Q99LN6**
- **DATABASE UNIPROT [Online] Q8FID6, 01 March 2003 'Putative uncharacterized protein' Retrieved from EBI, accession no. UNIPROT:Q8FID6 Database accession no. Q8FID6**
- **Kenneth Murphy ET AL: "Janeway's Immunobiology" In: "Janeway's Immunobiology", 2 January 2008 (2008-01-02), Taylor & Francis, XP055049307, ISBN: 978-0-81-534123-9 pages 129-132,**
- **GILLES GUICHARD ET AL: "Efficient Binding of Reduced Peptide Bond Pseudopeptides to Major Histocompatibility Complex Class I Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270, no. 44, 3 November 1995 (1995-11-03), pages 26057-26059, XP008153807, ISSN: 0021-9258, DOI: 10.1074/JBC.270.44.26057 [retrieved on 1995-11-03]**

EP 2 105 501 B1

Description

[0001] The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to a novel peptide sequence derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Background of the invention

[0002] Gliomas are brain tumors originating from glial cells in the nervous system. Glial cells, commonly called neuroglia or simply glia, are non-neuronal cells that provide support and nutrition, maintain homeostasis, form myelin, and participate in signal transmission in the nervous system. The two most important subgroups of gliomas are astrocytomas and oligodendrogliomas, named according to the normal glial cell type from which they originate (astrocytes or oligodendrocytes, respectively). Belonging to the subgroup of astrocytomas, glioblastoma multiforme (referred to as glioblastoma hereinafter) is the most common malignant brain tumor in adults and accounts for approx. 40% of all malignant brain tumors and approx. 50% of gliomas (CBTRUS, 2006). It aggressively invades the central nervous system and is ranked at the highest malignancy level (grade IV) among all gliomas. Although there has been steady progress in their treatment due to improvements in neuroimaging, microsurgery, diverse treatment options, such as temozolomide, and radiation, glioblastomas remain incurable (Macdonald, 2001; Burton and Prados, 2000; Prados and Levin, 2000). The lethal rate of this brain tumor is very high: the average life expectancy is 9 to 12 months after first diagnosis. The 5-year survival rate from 1986 to 1990 was 8.0%. To date, the five-year survival rate following aggressive therapy including gross tumor resection is still less than 10% (Burton and Prados, 2000; Nieder et al., 2000; Napolitano et al., 1999; Dazzi et al., 2000). Accordingly, there is a strong medical need for an alternative and effective therapeutic method.

[0003] Tumor cells of glioblastomas are the most undifferentiated ones among brain tumors, so the tumor cells have high potential of migration and proliferation and are highly invasive, leading to very poor prognosis. Glioblastomas lead to death due to rapid, aggressive, and infiltrative growth in the brain. The infiltrative growth pattern is responsible for the unresectable nature of these tumors. Glioblastomas are also relatively resistant to radiation and chemotherapy, and, therefore, post-treatment recurrence rates are high. In addition, the immune response to the neoplastic cells is rather ineffective in completely eradicating all neoplastic cells following resection and radiation therapy (Roth and Weller, 1999; Dix et al., 1999; Sablotzki et al., 2000).

[0004] Glioblastoma is classified into primary glioblastoma (*de novo*) and secondary glioblastoma, depending on differences in the gene mechanism during malignant transformation of undifferentiated astrocytes or glial precursor cells. Secondary glioblastoma occurs in a younger population of up to 45 years of age. During 4 to 5 years, on average, secondary glioblastoma develops from lower-grade astrocytoma through undifferentiated astrocytoma. In contrast, primary glioblastoma predominantly occurs in an older population with a mean age of 55 years. Generally, primary glioblastoma occurs as fulminant glioblastoma characterized by tumor progression within 3 months from the state with no clinical or pathological abnormalities (Pathology and Genetics of the Nervous Systems. 29-39 (IARC Press, Lyon, France, 2000)).

[0005] Glioblastoma migrates along myelinated nerves and spreads widely in the central nervous system. In most cases surgical treatment shows only limited sustainable therapeutic effect (Neurol. Med. Chir. (Tokyo) 34, 91-94, 1994; Neurol. Med. Chir. (Tokyo) 33, 425-458, 1993; Neuropathology 17, 186-188, 1997) (Macdonald, 2001; Prados and Levin, 2000).

[0006] Malignant glioma cells evade detection by the host's immune system by producing immunosuppressive agents that impair T cell proliferation and production of the immune-stimulating cytokine IL-2 (Dix et al., 1999).

[0007] Intracranial neoplasms can arise from any of the structures or cell types present in the CNS, including the brain, meninges, pituitary gland, skull, and even residual embryonic tissue. The overall annual incidence of primary brain tumors in the United States is 14 cases per 100,000.

[0008] The most common primary brain tumors are meningiomas, representing 27% of all primary brain tumors, and glioblastomas, representing 23% of all primary brain tumors (whereas glioblastomas account for 40% of malignant brain tumor in adults). Many of these tumors are aggressive and of high grade. Primary brain tumors are the most common solid tumors in children and the second most frequent cause of cancer death after leukemia in children.

[0009] The search for effective treatment of glioblastomas in patients is still ongoing today. Immunotherapy, or treatment via recruitment of the immune system, to fight these neoplastic cells has been investigated. First encouraging results were obtained in immuno-therapeutic studies in humans, in which antigen-specific CTL responses could be induced leading to prolonged median survival times compared to that obtained applying standard treatment accompanied by minimal toxicity (Heimberger et al., 2006).

[0010] WO 2005/116051 discloses immunogens against cancers/tumors, and a fragment from PTPRZ1 as immunogen.

[0011] The problem solved by the application at hand was therefore to establish a new efficacious and safe treatment option for brain tumors and to enhance the well-being of the patients without using chemotherapeutic agents or other agents which may lead to severe side effects.

Brief description of the principle of the invention

[0012] As used herein and except as noted otherwise, all terms are defined as given below.

[0013] The term "peptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are typically 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 14 amino acids in length.

[0014] The term "oligopeptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention, as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 14 amino acids in length.

[0015] The term "polypeptide" designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained. In contrast to the terms peptide or oligopeptide, the term polypeptide is meant to refer to protein molecules of longer than about 30 residues in length.

[0016] A peptide, oligopeptide, protein, or polynucleotide coding for such a molecule is "immunogenic" (and thus an "immunogen" within the present invention), if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a CTL-mediated response. Thus, an "immunogen" would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a CTL response.

[0017] A T cell "epitope" is a short peptide molecule that binds to a class I or II MHC molecule and that is subsequently recognized by a T cell. T cell epitopes that bind to class I MHC molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length. T cell epitopes that bind to class II MHC molecules are typically 12-30 amino acids in length. In the case of epitopes that bind to class II MHC molecules, the same T cell epitope may share a common core segment, but differ in the length of the carboxy- and amino-terminal flanking sequences due to the fact that ends of the peptide molecule are not buried in the structure of the class II MHC molecule peptide-binding cleft as they are in the class I MHC molecule peptide-binding cleft.

[0018] There are three different genetic loci that encode for class I MHC molecules: HLA-A, HLA-B, and HLA-C. HLA-A1, HLA-A2, and HLA-A11 are examples of different class I MHC molecules that can be expressed from these loci.

[0019] As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence. The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.

[0020] The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

[0021] The term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides.

[0022] The nucleotide sequence encoding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be synthetically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

[0023] The term "expression product" means the polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

[0024] The term "fragment," when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region, whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

[0025] The term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated

sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

[0026] The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

[0027] The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

[0028] The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

[0029] The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

[0030] The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, the claimed polypeptide which has a purity of preferably 99.999%, or at least 99.99% or 99.9%; and even desirably 99% by weight or greater is expressly contemplated.

[0031] The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form." As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01 %, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

[0032] The term "active fragment" means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune response taking the form of stimulating a CTL response within the recipient animal, such as a human. Alternatively, the "active fragment" may also be used to induce a CTL response in vitro.

[0033] As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. This means that any such fragment will necessarily contain as part of its amino acid sequence a segment, fragment or portion, that is substantially identical, if not exactly identical, to a sequence of SEQ ID NO: 1 to 10, which correspond to the naturally occurring, or "parent" proteins of the SEQ ID NO: 1 to 10. When used in relation to polynucleotides, such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.

[0034] In accordance with the present invention, the term "percent identity" or "percentidentical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100\,[I - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence, wherein

(i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and

(ii) each gap in the Reference Sequence and

(iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid

in the Compared Sequence, constitutes a difference;

and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

[0035] If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the herein above calculated Percent Identity is less than the specified Percent Identity.

[0036] The original peptides disclosed herein can be modified by the substitution of one or more residues at different, possibly selective, sites within the peptide chain. Such substitutions may be of a conservative nature, for example, where one amino acid is replaced by an amino acid of similar structure and characteristics, such as where a hydrophobic amino acid is replaced by another hydrophobic amino acid. Even more conservative would be replacement of amino acids of the same or similar size and chemical nature, such as where leucine is replaced by isoleucine. In studies of sequence variations in families of naturally occurring homologous proteins, certain amino acid substitutions are more often tolerated than others, and these are often show correlation with similarities in size, charge, polarity, and hydrophobicity between the original amino acid and its replacement, and such is the basis for defining "conservative substitutions."

[0037] Conservative substitutions are herein defined as exchanges within one of the following five groups: Group 1--small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2--polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3-polar, positively charged residues (His, Arg, Lys); Group 4--large, aliphatic, nonpolar residues (Met, Leu, lie, Val, Cys); and Group 4--large, aromatic residues (Phe, Tyr, Trp).

[0038] Less conservative substitutions might involve the replacement of one amino acid by another that has similar characteristics but is somewhat different in size, such as replacement of an alanine by an isoleucine residue. Highly non-conservative replacements might involve substituting an acidic amino acid for one that is polar, or even for one that is basic in character. Such "radical" substitutions cannot, however, be dismissed as potentially ineffective since chemical effects are not totally predictable and radical substitutions might well give rise to serendipitous effects not otherwise predictable from simple chemical principles.

[0039] Of course, such substitutions may involve structures other than the common L-amino acids. Thus, D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure herein. In addition, amino acids possessing non-standard R groups (i.e., R groups other than those found in the common 20 amino acids of natural proteins) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.

[0040] If substitutions at more than one position are found to result in a peptide with substantially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or synergistic effects on the antigenicity of the peptide. At most, no more than 4 positions within the peptide would simultaneously be substituted.

[0041] Based on cytotoxicity assays, an epitope is considered substantially identical to the reference peptide if it has at least 10% of the antigenic activity of the reference peptide as defined by the ability of the substituted peptide to reconstitute the epitope recognized by a CTL in comparison to the reference peptide. Thus, when comparing the lytic activity in the linear portion of the effector:target curves with equimolar concentrations of the reference and substituted peptides, the observed percent specific killing of the target cells incubated with the substituted peptide should be equal to that of the reference peptide at an effector:target ratio that is no greater than 10-fold above the reference peptide effector:target ratio at which the comparison is being made.

[0042] Preferably, when the CTLs specific for a peptide of SEQ ID NO: 1 to 10 are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 μM, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals.

[0043] Thus, the epitopes of the present invention may be identical to naturally occurring tumor-associated or tumor-specific epitopes or may include epitopes that differ by no more than 4 residues from the reference peptide, as long as they have substantially identical antigenic activity.

[0044] Stimulation of an immune response is dependent upon the presence of antigens recognised as foreign by the host immune system. The discovery of the existence of tumor associated antigens has now raised the possibility of using a host's immune system to foster an immune response which is specific for target antigens expressed on the surface of tumor cells and which through this mechanism of action is capable of inducing regression, stasis or slowed-down growth of the tumor. Various mechanisms of harnessing both the humoral and cellular arms of the immune system are currently being explored for cancer immunotherapy.

[0045] Specific elements of the cellular immune response are capable of specifically recognising and destroying tumor

cells. The isolation of cytotoxic T cells (CTL) from tumor-infiltrating cell populations or from peripheral blood suggests that such cells play an important role in natural immune defences against cancer (Cheever et al., 1993; Zeh, III et al., 1999). Based on the analysis of 415 specimens from patients suffering from colorectal cancer, Galon et al. were able to demonstrate that type, density and location of immune cells in tumor tissue are actually a better predictor for survival of patients than the widely employed TNM-staging of tumors (Galon et al., 2006). CD8-positive T cells ($TCD8^+$) in particular, which recognise Class I molecules of the major histocompatibility complex (MHC)-bearing peptides of usually 8 to 10 amino acid residues derived from proteins, defective ribosomal products (DRIPs) (Schubert et al., 2000), play an important role in this response. Also peptides stemming from spliced proteins were described in the literature. The MHC-molecules of the human are also designated human leukocyte antigens (HLA).

[0046] There are two classes of MHC-molecules: MHC class I molecules that can be found on most cells having a nucleus. MHC molecules are composed of a alpha heavy chain and beta-2-microglobulin (MHC class I receptors) or an alpha and a beta chain (MHC class II receptors), respectively. Their three-dimensional conformation results in a binding groove, which is used for non-covalent interaction with peptides. MHC class I present peptides that result from proteolytic cleavage of predominantly endogenous proteins, DRIPs and larger peptides. MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs), and primarily present peptides of exogenous or transmembrane proteins that are taken up by APCs during the course of endocytosis, and are subsequently processed (Cresswell, 1994). Complexes of peptide and MHC class I molecules are recognized by CD8-positive cytotoxic T-lymphocytes bearing the appropriate TCR (T-cell receptor), complexes of peptide and MHC class II molecules are recognized by CD4-positive-helper-T cells bearing the appropriate TCR It is well known that the TCR, the peptide and the MHC are thereby present in a stoichiometric amount of 1:1:1.

[0047] CD4-positive helper T cells play an important role in inducing and sustaining effective responses by CD8-positive cytotoxic T cells (Wang and Livingstone, 2003; Sun and Bevan, 2003; Shedlock and Shen, 2003). For this reason, the identification of CD4-positive T-cell epitopes derived from tumor associated antigens (TAA) is of great importance for the development of pharmaceutical products for triggering anti-tumor immune responses (Kobayashi et al., 2002; Qin et al., 2003; Gnjatic et al., 2003).

[0048] In the absence of inflammation, expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells. In cancer patients, cells of the tumor have surprisingly been found to express MHC class II molecules (Dengjel et al., 2006).

[0049] It was shown in mammalian animal models, e.g., mice, that even in the absence of CTL effector cells (i.e., CD8-positive T lymphocytes), CD4-positive T cells are sufficient for inhibiting manifestation of tumors via inhibition of angiogenesis by secretion of interferon-gamma ($IFN\gamma$) (Qin and Blankenstein, 2000). Additionally, it was shown that CD4-positive T cells recognizing peptides from tumor-associated antigens presented by HLA class II molecules can counteract tumor progression via the induction of antibody (Ab) responses (Kennedy et al., 2003). In contrast to tumor-associated peptides binding to HLA class I molecules, only a small number of class II ligands of TAA have been described so far (www.cancerimmunity.org, www.syfpeithi.de).

[0050] Since the constitutive expression of HLA class II molecules is usually limited to cells of the immune system (Mach et al., 1996), the possibility of isolating class II peptides directly from primary tumors was not considered possible. However, Dengjel et al. were recently successful in identifying a number of MHC Class II epitopes directly from tumors (WO 2007/028574, EP 1 760 088 B1; (Dengjel et al., 2006).

[0051] For a peptide to trigger (elicit) a cellular immune response, it must bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule and specific polymorphisms of the amino acid sequence of the peptide. MHC-class-I-binding peptides are usually 8-10 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC-molecule. In this way each MHC allele has a "binding motif" determining which peptides can bind specifically to the binding groove (Rammensee et al., 1997).

[0052] In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules being expressed by tumor cells, they also have to be recognized by T cells bearing specific T cell receptors (TCR).

[0053] The antigens that are recognized by the tumor specific cytotoxic T lymphocytes, that is, their epitopes, can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, up-regulated in cells of the respective tumor.

[0054] The current classification of tumor associated antigens comprises the following major groups (Novellino et al., 2005):

1. Cancer-testis antigens: The first TAAs ever identified that can be recognized by T cells (van der Bruggen et al., 1991) belong to this class, which was originally called cancer-testis (CT) antigens because of the expression of its members in histologically different human tumors and, among normal tissues, only in spermatocytes/spermatogonia

of testis and, occasionally, in placenta. Since the cells of testis do not express class I and II HLA molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered as immunologically tumor-specific. Well-known examples for CT antigens are the MAGE family members or NY-ESO-1.

2. Differentiation antigens: These TAAs are shared between tumors and the normal tissue from which the tumor arose; most are found in melanomas and normal melanocytes. Many of these melanocyte lineage-related proteins are involved in the biosynthesis of melanin and are therefore not tumor specific but nevertheless are widely used for cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma or PSA for prostate cancer.

3. Overexpressed TAAs: Genes encoding widely expressed TAAs have been detected in histologically different types of tumors as well as in many normal tissues, generally with lower expression levels. It is possible that many of the epitopes processed and potentially presented by normal tissues are below the threshold level for T-cell recognition, while their overexpression in tumor cells can trigger an anticancer response by breaking previously established tolerance. Prominent examples for this class of TAAs are Her-2/neu, Survivin, Telomerase or WT1.

4. Tumor specific antigens: These unique TAAs arise from mutations of normal genes (such as β-catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and/or progression. Tumor specific antigens are generally able to induce strong immune responses without bearing the risk for autoimmune reactions against normal tissues. On the other hand, these TAAs are in most cases only relevant to the exact tumor on which they were identified and are usually not shared between many individual tumors.

5. TAAs arising from abnormal post-translational modifications: Such TAAs may arise from proteins which are neither specific nor overexpressed in tumors but nevertheless become tumor associated by posttranslational processes primarily active in tumors. Examples for this class arise from altered glycosylation patterns leading to novel epitopes in tumors as for MUC1 or events like protein splicing during degradation which may or may not be tumor specific (Hanada et al., 2004; Vigneron et al., 2004).

6. Oncoviral proteins: These TAAs are viral proteins that may play a critical role in the oncogenic process and, because they are foreign (not of human origin), they can evoke a T-cell response. Examples of such proteins are the human papilloma type 16 virus proteins, E6 and E7, which are expressed in cervical carcinoma.

[0055] For proteins to be recognized by cytotoxic T-lymphocytes as tumor-specific or -associated antigens, and in order to be used in a therapy, particular prerequisites must be fulfilled. The antigen should be expressed mainly by tumor cells and not or in comparably small amounts by normal healthy tissues. It is furthermore desirable, that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers of the respective peptide per cell). Tumor-specific and tumor-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumor cell due to a function e.g. in cell cycle control or suppression of apoptosis. Additionally, also downstream targets of the proteins directly causative for a transformation may be upregulated und thus may be indirectly tumor-associated. Such indirectly tumor-associated antigens may also be targets of a vaccination approach (Singh-Jasuja et al., 2004). In both cases it is essential that epitopes are present in the amino acid sequence of the antigen, since such a peptide ("immunogenic peptide") that is derived from a tumor associated antigen should lead to an in vitro or in vivo T-cell-response.

[0056] Basically, any peptide able to bind a MHC molecule may function as a T-cell epitope. A prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T cell with a corresponding TCR and the absence of immunological tolerance for this particular epitope.

[0057] Therefore, TAAs are a starting point for the development of a tumor vaccine. The methods for identifying and characterizing the TAAs are based on the use of CTL that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues (Lemmel et al., 2004; Weinschenk et al., 2002).

[0058] However, the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune therapy. This is because only an individual subpopulation of epitopes of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and immunological tolerance for this particular epitope needs to be absent or minimal. It is therefore important to select only those peptides from over-expressed or selectively expressed proteins that are presented in connection with MHC molecules against which a functional T cell can be found. Such a functional T cell is defined as a T cell which upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T cell"). Typical effector functions of T cells include the secretion of Interferon-gamma, perforin, and granzymes.

[0059] T-helper cells play an important role in orchestrating the effector function of CTLs in anti-tumor immunity. T-helper cell epitopes that trigger a T-helper cell response of the T_{H1} type support effector functions of CD8-positive killer T cells, which include cytotoxic functions directed against tumor cells displaying tumor-associated peptide/MHC complexes on their cell surfaces. In this way tumor-associated T-helper cell peptide epitopes, alone or in combination with

other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses.

[0060] Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumor effect, the identification and characterization of tumor-associated antigens being recognized by either CD8+ CTLs (ligand: MHC class I molecule + peptide epitope) or by CD4-positive T-helper cells (ligand: MHC class II molecule + peptide epitope) is important in the development of tumor vaccines.

[0061] It is therefore an object of the present invention, to provide novel amino acid sequences for peptides that are able to bind to MHC complexes of either class.

Brief description of the drawings

[0062]

Fig. 1a and b show the ESI-liquid chromatography mass spectra identifying tumor associated peptides (TUMAPs) PTP-001 from glioblastoma sample GB1006 and PTP-002 from glioblastoma sample GB6003 that were presented in a MHC class I-restricted manner.

Fig. 2 depicts the mRNA expression profile of the gene PTPRZ1 encoding the glioblastoma associated peptides shown in Table 1. Expression of this gene is absent or very low in normal tissues while it is strongly increased in glioblastoma samples (GB1006T to GB1011T; NCH359T and NCH361T).

Figure 3 shows a representative example for PTP-002-specific CD8+ T cells in one healthy HLA-A*0201 donor following *in vitro* stimulation with PTP-002 as determined by flow cytometric analysis. CD8+ T cells were isolated from healthy donor human PBMCs and primed *in vitro* using molecularly defined "artificial antigen presenting cells" (aAPCs) loaded with co-stimulatory molecules and A*0201/PTP-002 (left diagram) or irrelevant A*0201 peptide (right diagram) (Walter et al., 2003). After three cycles of stimulation, the detection of peptide-reactive cells was performed by staining with PTP-002- plus irrelevant peptide tetramers. Cells were gated on CD8+ lymphocyte population and percentages represent the frequencies of tetramer-positive cells within this population.

Detailed description of the invention

[0063] The present invention provides peptides that are useful in treating glioblastoma. These peptides were directly shown by mass spectrometry to be naturally presented by HLA molecules on primary human glioblastoma samples (see example 1. and figure 1). The source gene from which these peptides are derived - PTPRZ1 - was shown to be highly overexpressed in glioblastoma compared with normal tissues (see example 2 and figure 2) demonstrating a high degree of tumor association of these peptides, i.e. these peptides are strongly presented on tumor tissue but not on normal tissues. HLA-bound peptides can be recognized by the immune system, specifically T lymphocytes/T cells. T cells can destroy the cells presenting the recognized HLA/peptide complex, e.g. glioblastoma tumor cells presenting the PTPRZ1-derived peptides. Several peptides of the present invention have been shown to be capable of stimulating T cell responses (see Example3 and figure 3.) Thus, the peptides are useful for generating an immune response in a patient by which tumor cells can be destroyed. An immune response in a patient can be induced by direct administration of the described peptides or suitable precursor substances (e.g. elongated peptides, proteins, or nucleic acids encoding these peptides) to the patient, ideally in combination with an agent enhancing the immunogenicity (i.e. an adjuvant). The immune response originating from such a therapeutic vaccination can be expected to be highly specific against tumor cells because the target peptides of the present invention are not presented on normal tissues, preventing the risk of undesired autoimmune reactions against normal cells in the patient.

[0064] In addition to being useful for treating cancer, the peptides of the present invention are also useful as diagnostics. Since the peptides were generated from glioblastoma and since it was determined that these peptides are not present in normal tissues, these peptides can be used to diagnose the presence of a cancer.

[0065] The presence of claimed TUMAPs on tissue biopsies can assist a pathologist in diagnosis of cancer. Detection of certain TUMAPs by means of antibodies, mass spectrometry or other methods known in the art can tell the pathologist that the tissue is malignant or inflamed or generally diseased. Presence of groups of TUMAPs can enable classification or subclassification of diseased tissues.

[0066] The detection of TUMAPs on diseased tissue specimen can enable the decision about the benefit of therapies involving the immune system, especially if T lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well described mechanism by which infected of malignant cells escape immuno-surveillance. Thus, presence of TUMAPs shows that this mechanism is not exploited by the analyzed cells.

[0067] TUMAPs might be used to analyze lymphocyte responses against those TUMAPs such as T cell responses or

antibody responses against the TUMAP or the TUMAP complexed to MHC molecules. These lymphocyte responses can be used as prognostic markers for decision on further therapy steps. These responses can also be used as surrogate markers in immunotherapy approaches aiming to induce lymphocyte responses by different means, e.g. vaccination of protein, nucleic acids, autologous materials, adoptive transfer of lymphocytes. In gene therapy settings, lymphocyte responses against TUMAPs can be considered in the assessment of side effects. Monitoring of lymphocyte responses might also be a valuable tool for follow-up examinations of transplantation therapies, e.g. for the detection of graft versus host and host versus graft diseases.

[0068] TUMAPs can be used to generate and develop specific antibodies against MHC/TUMAP complexes. These can be used for therapy, targeting toxins or radioactive substances to the diseased tissue. Another use of these antibodies can be targeting radionuclides to the diseased tissue for imaging purposes such as PET. This use can help to detect small metastases or to determine the size and precise localization of diseased tissues.

[0069] In addition, they can be used to verify a pathologist's diagnosis of a cancer based on a biopsied sample.

[0070] Table 1 shows the peptides as described in the present invention, their respective SEQ ID NO, the HLA alleles to which the respective peptides bind, and the source proteins from which these peptides may arise.

Table 1: Peptides as described, SEQ ID NO 1 is of the present invention

SEQ ID NO	Peptide Code	Sequence	HLA Alleles	Source Protein(s)
1	PTP-001	ALTTLMHQL	A*0205	PTPRZ1
2	PTP-002	FLYKVILSL	A*02	PTPRZ1
3	PTP-003	AIIDGVESV	A*02	PTPRZ1
4	PTP-004	FLLPDTDGL	A*02	PTPRZ1
5	PTP-005	KVFAGIPTV	A*02	PTPRZ1
6	PTP-006	QQSDYSAAL	A*02#	PTPRZ1
7	PTP-007	TQDDYVLEV	A*02#	PTPRZ1, PTPRG
8	PTP-008	QHEGTVNIF	B*38	PTPRZ1
9	PTP-009	SVFGDDNKALSK	Not determined	PTPRZ1
10	PTP-010	EIGWSYTGALNQKN	HLA-DR	PTPRZ1
# probably subtype A*205				

Protein Tyrosine Phosphatase, Receptor-Type, Zeta1 (PTPRZ1, PTP-ξ)

[0071] PTPRZ1 is a member of the receptor type protein tyrosine phosphatase family and encodes a single-pass type I membrane protein with two cytoplasmatic tyrosine-protein phosphatase domains, an alpha-carbonic anhydrase domain and a fibronectin type-III domain. (Wu et al., 2006), in breast cancer (Perez-Pinera et al., 2007), in the remyelinating oligodendrocytes of multiple sclerosis lesions (Harroch et al., 2002), and in human embryonic kidney cells under hypoxic conditions (Wang et al., 2005).

[0072] Both the protein and transcript are overexpressed in glioblastoma cells, promoting their haptotactic migration (Lu et al., 2005). Furthermore, PTRPZ1 is frequently amplified at the genomic DNA level in glioblastoma (Mulholland et al., 2006).

[0073] Kaplan et al. cloned 3 human receptor PTP genes, including PTP-γ (Kaplan et al., 1990). It was shown that one PTPG allele was lost in 3 of 5 renal carcinoma cell lines and in 5 of 10 lung carcinoma tumor samples tested. PTP-γ mRNA was expressed in kidney cell lines and lung cell lines but not in several hematopoietic cell lines tested. Thus, the PTP-γ gene appeared to have characteristics suggesting that it may be a tumor suppressor gene in renal and lung carcinoma. Gebbink et al. isolated a mouse cDNA of 5.7 kb, encoding a 'new' member of the family of receptor-like protein-tyrosine phosphatases, termed RPTPμ (Gebbink et al., 1991). The cDNA predicted a protein of 1,432 amino acids (not including the signal peptide) with a calculated molecular mass of 161,636 Da. In addition, they cloned the human homolog, which showed 98.7% amino acid homology to the mouse protein. The predicted mouse protein consisted of a 722-amino acid extracellular region, containing 13 potential N-glycosylation sites, a single transmembrane domain, and a 688-amino acid intracellular part containing two tandem repeats homologous to the catalytic domains of other tyrosine phosphatases. RNA blot analysis showed a single transcript that was most abundant in lung but present in much lower amounts in brain and heart as well. The human PTPμ gene was assigned to 18pter-qll by Southern analysis of human/rodent somatic cell hybrid clones.

[0074] The PTP-ε cDNA was isolated by Krueger et al. (Krueger et al., 1990). The 700-amino acid protein has a short extracellular domain and two tandemly repeated intracellular PTPase domains. High levels of PTP-e transcription were

noted in the mouse brain and testes. Both isoforms of PTP- ε - transmembrane, receptor-type isoform and a shorter, cytoplasmic one - appear to arise from a single gene through the use of alternative promoters and 5-prime exons.

[0075] Barnea et al. (Bamea et al., 1993) cloned cDNAs for the human and mouse PTP-γ gene (designated PTP-γ by that group) from brain cDNA libraries, and analyzed their predicted polypeptide sequences. The human (1,445-amino acid) and mouse (1,442-amino acid) sequences share 95% identity at the amino acid level and predict a putative extracellular domain, a single transmembrane domain, and a cytoplasmatic region with 2 tandem catalytic tyrosine phosphatase domains. The extracellular domain contains a stretch of 266 amino acids that are highly similar to the zinc-containing enzyme carbonic anhydrase (MIM 114800), suggesting that PTP-γ and PTP-ξ (PTPRZ1) represent a subfamily of 25 receptor tyrosine phosphatases. The gene for PTP-γ has 30 exons and is approximately 780 kb in size. It is much larger than the other receptor PTP genes, with the CD45 gene (MIM 151460) being around 100 kb and the others even smaller.

[0076] Another receptor-type tyrosine phosphatase, protein tyrosine phosphatase zeta (PTPRZ1) [also known as PTP-ξ, HPTP-ZETA, HPTPZ, RPTP-BETA(β), or RPTPB] was isolated as a cDNA sequence by two groups in the early nineties. Levy et al. (Levy et al., 1993) isolated cDNA clones from a human infant brainstem mRNA expression library, and deduced the complete amino acid sequence of a large receptor-type protein tyrosine phosphatase containing 2,307 amino acids.

[0077] Levy found that the protein, which they designated PTPβ (PTPRZ1), is a transmembrane protein with two cytoplasmic PTPase domains and a 1,616-amino acid extracellular domain. As in PTP-γ (MIM 176886), the 266 N-terminal residues of the extracellular domain have a high degree of similarity to carbonic anhydrases (see MIM 114880). The human gene encoding PTPRZ1 has been mapped to chromosome 7q31.3-q32 by chromosomal in situ hybridization (Ariyama et al., 1995). Northern blot analysis has shown that showed that PTP-zeta is expressed only in the human central nervous system. By in situ hybridization, (Levy et al., 1993) localized the expression to different regions of the adult human brain, including the Purkinje cell layer of the cerebellum, the dentate gyms, and the subependymal layer of the anterior horn of the lateral ventricle. Levy stated that this was the first mammalian tyrosine phosphatase whose expression is restricted to the nervous system. In addition, high levels of expression in the murine embryonic brain suggested an important role in CNS development.

[0078] Thus, the PTP receptor family of proteins has been characterized as a fairly diverse family of membrane-bound receptors, and non-membrane bound isoforms, which share a common PTPase cytosol domain architecture. Although their expression in fetal and embryonic tissues has suggested a developmental biology role for the proteins, their full function in normal and disease state biology is still not fully understood.

[0079] US 6,455,026 identified PTP-ξ (PTPRZ1) as a target in the treatment and visualization of brain tumors. The application provided methods and reagents for specifically targeting brain tumor cells for both therapeutic and imaging purposes. PTP-ξ affinity-based compounds and compositions useful in treating a brain tumor in a patient were provided, whereas the compositions and compounds generally fell into two groups: PTP-ξ -binding conjugate compounds, which comprise a cytotoxic moiety, which inhibits the growth of tumor cells; and PTP-ξ-binding compound compositions in which the PTP-ξ binding moiety alters the normal function of PTP-ξ in the tumor cell, thus inhibiting cell growth.

[0080] In a first group, PTP ξ-binding therapeutic conjugate compounds were provided. These compounds had the general formula $\alpha(P_z)C$, wherein $\alpha(P_z)$ were one or more moieties which specifically bound to a human protein tyrosine phosphatase-ξ, and C was one or more cytotoxic moieties. In preferred embodiments (which was disclosed for all groups) $\alpha(P_z)$ was disclosed to be an antibody or an antibody fragment. In a second group PTP-ξ -binding therapeutic compounds were provided which altered the normal function of PTP-ξ in brain tumor cells and inhibited brain tumor cell growth. These PTPRZ1 -binding therapeutic compounds had the general formula $\alpha(P_z)$ wherein $\alpha(P_z)$ were one or more moieties which specifically bound to a human protein tyrosine phosphatase- ξ, and wherein the binding of $\alpha(P_z)$ altered the function of protein tyrosine phosphatase- ξ.

[0081] US 7,060,275 B2 discloses splicing variants of PTPRZ1, vectors including these variants and antigens against various variants.

[0082] Nowhere in the prior art, the use of MHC-binding peptides derived from PTPRZ1 as active pharmaceutical ingredients for the treatment of brain tumors has been considered.

[0083] In a first aspect thereof, the present invention thus provides a peptide consisting of the amino acid sequence according to SEQ ID No. 1.

[0084] The peptides of the invention have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I.

[0085] In the present invention, the term "homologous" refers to the degree of identity between sequences of two amino acid sequences, i.e. peptide or polypeptide sequences. The aforementioned "homology" is determined by comparing two sequences aligned under optimal conditions over the sequences to be compared. The sequences to be compared herein may have an addition or deletion (for example, gap and the like) in the optimum alignment of the two sequences. Such a sequence homology can be calculated by creating an alignment using, for example, the ClustalW algorithm (Nucleic Acid Res., 22(22): 4673 4680 (1994). Commonly available sequence analysis software, more spe-

cifically, Vector NTI, GENETYX or analysis tools provided by public databases, such as e.g. http://restools.sdsc.edu/biotools/biotools16.html may also be used.

[0086] A person skilled in the art will be able to assess, whether T cells induced by a variant of a specific peptide will be able to cross-react with the peptide itself (Fong et al., 2001b); (Zaremba et al., 1997; Colombetti et al., 2006; Appay et al., 2006).

[0087] As can be derived from the scientific literature (Rammensee et al., 1997) and databases (Rammensee et al., 1999), certain positions of HLA binding peptides are typically anchor residues forming a core sequence fitting to the binding motif of the HLA receptor, which is defined by polar, electrophysical, hydrophobic and spatial properties of the polypeptide chains constituting the binding groove. Thus one skilled in the art would be able to modify the amino acid sequences set forth in SEQ ID No:1-10, by maintaining the known anchor residues, and would be able to determine whether such variants maintain the ability to bind MHC class I molecules.

[0088] Those amino acid residues that do not substantially contribute to interactions with the T-cell receptor can be modified by replacement with another amino acid whose incorporation does not substantially affect T-cell reactivity and does not eliminate binding to the relevant MHC. Thus, apart from the proviso given, the peptide of the invention may be any peptide (by which term the inventors include oligopeptide or polypeptide) which includes the amino acid sequences or a portion or variant thereof as given.

Table 2 Variants and motif of the peptides according to SEQ. ID 1 to 10

PTP-001		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		A	**L**	T	T	L	M	H	Q	**L**
	Variants		V		P	E	V	I	H	Y	
			Y		F	D	L	V	V		
					I	K	I	L			
					M	N		A			
						P					
		Position	1	2	3	4	5	6	7	8	9
PTP-002	Peptide Code		F	**L**	Y	K	V	I	L	S	**L**
	Variants			M							L
						E				K	
			I		A	G	I	I	A	E	
			L		Y	P	K	L	Y	S	
			F		F	D	Y	T	H		
			K		P	T	N				
			M		M		G				
			Y		S		F				
			V		R		V				
						K	H				
PTP-003		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		A	**I**	I	D	G	V	E	S	**V**
	Variants			M							L
				L							L
						E				K	
			I		A	G	I	I	A	E	

(continued)

PTP-003		Position	1	2	3	4	5	6	7	8	9
			L		Y	P	K	L	Y		
			F		F	T	Y	T	H		
			K		P		**N**				
			M		M		F				
			Y		S		V				
			V		R						
PTP-004		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		F	**L**	L	P	D	T	D	G	**L**
	Variants			M							L
						E				K	
			I		A	G	I	I	A	E	
			L		Y	D	K	L	Y	S	
			K		F	T	Y		H		
			M		P		**N**				
			Y		M		G				
			V		S		F				
					R		V				
						K	H				
PTP-005		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		K	**V**	F	A	G	I	P	T	**V**
	Variants			M							L
				L							L
						E				K	
			I		A	G	I		A	E	
			L		Y	P	K	L	Y		
			F		P	T	Y	T	H		
			M		M		**N**				
			Y		S		F				
							V				
PTP-006		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		Q	**Q**	s	D	Y	S	A	A	**L**
	Variants		V		P	E	V	I	H	Y	
			Y		F	K	L	V	V		
					I	**N**	I	L			
					M	P		A			

(continued)

PTP-007		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		T	**Q**	D	D	Y	V	L	E	**V**
	Variants		V		P	E	V	I	H	Y	L
			Y		F	K	L	V	V		
					I	N	I	L			
					M	P		A			
PTP-008		Position	1	2	3	4	5	6	7	8	9
	Peptide Code		Q	**H**	**E**	G	T	V	N	I	**F**
	Variants				D						
			I			E	M	V	Y	K	
						P	V	I	V	Y	
						L	A	T	N	N	
						E	R	K		R	
						G	N				
						L	H				
						K					
						S					

[0089] It is furthermore known for MHC-class II-presented peptides that these peptides are composed of a "core sequence" having an amino acid sequence fitting to a certain HLA-allele-specific motif and, optionally, N- and/or C-terminal extensions which do not interfere with the function of the core sequence (i.e. are deemed as irrelevant for the interaction of the peptide and all or a subset of T cell clones recognising the natural counterpart). The N- and/or C-terminal extensions can, for example, be between 1 to 10 amino acids in length, respectively. These peptides can be used either directly in order to load MHC class II molecules or the sequence can be cloned into the vectors according to the description herein below. As these peptides constitute the final product of the processing of larger peptides within the cell, longer peptides can be used as well. The peptides as described may be of any size, but typically they may be less than 100.000 in molecular weight, preferably less than 50.000, more preferably less than 10.000 and typically about 5.000. In terms of the number of amino acid residues, the peptides as described may have fewer than 1.000 residues, preferably fewer than 500 residues, more preferably fewer than 100, more preferably fewer than 100 and most preferably between 30 and 8 residues.

[0090] Correspondingly, naturally occurring or artificial variants that induce T cells cross-reacting with a peptide of the invention are often length variants.

[0091] If a peptide which is longer than around 12 amino acid residues is used directly to bind to a MHC class II molecule, it is preferred that the residues that flank the core HLA binding region are ones that do not substantially affect the ability of the peptide to bind specifically to the binding groove of the MHC class II molecule or to present the peptide to the T (-helper) cell. However, as already indicated above, it will be appreciated that larger peptides may be used, e.g. when encoded by a polynucleotide, since these larger peptides may be fragmented by suitable antigen-presenting cells.

[0092] It is also possible, that MHC class I epitopes, although usually between 8-10 amino acids long, are generated by peptide processing from longer peptides or proteins that include the actual epitope. It is preferred that the residues that flank the actual epitope are ones that do not substantially affect proteolytic cleavage necessary to expose the actual epitope during processing.

[0093] Of course, the peptide according to the present invention will have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I. Binding of a peptide or a variant to a MHC complex may be tested by methods known in the art, for example those described in the literature for different MHC class II alleles (e.g. (Vogt et al., 1994; Malcherek et al., 1994; Manici et al., 1999; Hammer et al., 1995; Tompkins et al., 1993; Boyton et al., 1998)).

[0094] The peptide of the invention-consists of an amino acid sequence according to SEQ ID No. 1.

[0095] In one embodiment of the present invention, the peptide is part of a fusion protein which comprises the 80 N-

terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, in the following "Ii") as derived from the NCBI, GenBank Accession-number X00497 (Strubin, M. et al 1984).

[0096] Examples for further described peptides are those, peptide is selected from a peptide having a specific HLA-subtype and is capable of stimulating CD8 cells, and wherein said peptide comprises the specific anchor amino acid-motif as depicted in the following table 2a:

Table 2a HLA-subtypes and anchor motifs of preferred peptides

Peptide	HLA-subtype		Position	1	2	3	4	5	6	7	8	9
1	A*0205	Peptide Code		A	**L**	T	T	L	M	H	Q	**L**
		Anchor motif		x	L	x	x	x	x	x	x	L
2	A*02	Peptide Code		F	**L**	Y	K	V	I	L	S	**L**
		Anchor motif		x	L	x	x	x	x	x	x	L
3	A*02	Peptide Code		A	**I**	I	D	G	V	E	S	**V**
		Anchor motif		x	I	x	x	x	x	x	x	V
4	A*02	Peptide Code		F	**L**	L	P	D	T	D	G	**L**
		Anchor motif		X	L	X	X	X	X	X	x	L
5	A*02	Peptide Code		K	**V**	F	A	G	I	P	T	**V**
		Anchor motif		x	V	x	x	x	x	x	x	V
6	A*02 (probably subtype A*205)	Peptide Code		Q	**Q**	s	D	Y	S	A	A	**L**
		Anchor motif		x	Q	x	x	x	x	x	x	L
7	A*02 (probably subtype A*205)	Peptide Code		T	**Q**	D	D	Y	V	L	E	**V**
		Anchor motif		x	Q	x	x	x	x	x	x	V
8	B*38	Peptide Code		Q	**H**	**E**	G	T	V	N	I	**F**
		Anchor motif		x	H	E	x	x	x	x	x	F
X	A*02	General anchor motif for peptides		x	L/I/V	x	x	x	x	x	x	L/V

[0097] In a reverse peptide bond amino acid residues are not joined by peptide (-CO-NH-) linkages but the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) J. Immunol. 159, 3230-3237. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Meziere et al (1997) show that for MHC binding and T helper cell responses, these pseudopeptides are useful. Retro-inverse peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.

[0098] A non-peptide bond is, for example, $-CH_2-NH$, $-CH_2S-$, $-CH_2CH_2-$, $-CH=CH-$, $-COCH_2-$, $-CH(OH)CH_2-$, and $-CH_2SO-$. United States Patent 4,897,445 provides a method for the solid phase synthesis of non-peptide bonds ($-CH_2-NH$) in polypeptide chains which involves polypeptides synthesised by standard procedures and the non-peptide bond synthesised by reacting an amino aldehyde and an amino acid in the presence of $NaCNBH_3$.

[0099] Peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, such that, for example, the stability, bioavailability, and/or affinity of the peptides are enhanced. For example, hydrophobic groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxycarbonyl group may be placed at the peptides' amino termini. Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini.

[0100] Further, the peptides as described may be synthesized such that their steric configuration is altered. For example, the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer. Still further, at least one of the amino acid residues of the peptides of the invention may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bio-

availability and/or binding action of the peptides of the invention.

[0101] Similarly, a peptide as described may be modified chemically by reacting specific amino acids either before or after synthesis of the peptide. Examples for such modifications are well known in the art and are summarised e.g. in R. Lundblad, Chemical Reagents for Protein Modification, 3rd ed. CRC Press, 2005. Chemical modification of amino acids includes but is not limited to, modification by acylation, amidination, pyridoxylation of lysine, reductive alkylation, trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amide modification of carboxyl groups and sulphydryl modification by performic acid oxidation of cysteine to cysteic acid, formation of mercurial derivatives, formation of mixed disulphides with other thiol compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide and carbamoylation with cyanate at alkaline pH, although without limitation thereto. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science, Eds. Coligan et al. (John Wiley & Sons NY 1995-2000) for more extensive methodology relating to chemical modification of proteins.

[0102] Briefly, modification of e.g. arginyl residues in proteins is often based on the reaction of vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2-cyclohexanedione to form an adduct. Another example is the reaction of methylglyoxal with arginine residues. Cysteine can be modified without concomitant modification of other nucleophilic sites such as lysine and histidine. As a result, a large number of reagents are available for the modification of cysteine. The websites of companies such as Sigma-Aldrich (http://www.sigma-aldrich.com) provide information on specific reagents.

[0103] Selective reduction of disulfide bonds in proteins is also common. Disulfide bonds can be formed and oxidized during the heat treatment of biopharmaceuticals.

[0104] Woodward's Reagent K may be used to modify specific glutamic acid residues. N-(3-(dimethylamino)propyl)-N'-ethylcarbodiimide can be used to form intra-molecular crosslinks between a lysine residue and a glutamic acid residue.

[0105] For example, diethylpyrocarbonate is a reagent for the modification of histidyl residues in proteins. Histidine can also be modified using 4-hydroxy-2-nonenal.

[0106] The reaction of lysine residues and other α-amino groups is, for example, useful in binding of peptides to surfaces or the cross-linking of proteins/peptides. Lysine is the site of attachment of poly(ethylene)glycol and the major site of modification in the glycation of proteins.

[0107] Methionine residues in proteins can be modified with e.g. iodoacetamide, bromoethylamine, and chloramine T.

[0108] Tetranitromethane and N-acetylimidazole can be used for the modification of tyrosyl residues. Cross-linking via the formation of dityrosine can be accomplished with hydrogen peroxide/copper ions.

[0109] Recent studies on the modification of tryptophan have used N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide or 3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-indole (BPNS-skatole).

[0110] Successful modification of therapeutic proteins and peptides with PEG is often associated with an extension of circulatory half-life while cross-linking of proteins with glutaraldehyde, polyethyleneglycol diacrylate and formaldehyde is used for the preparation of hydrogels. Chemical modification of allergens for immunotherapy is often achieved by carbamylation with potassium cyanate.

[0111] A peptide wherein the peptide is modified or includes non-peptide bonds is described. Generally, peptides (at least those containing peptide linkages between amino acid residues) may be synthesised by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lu et al (1981) and references therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities. The solid-phase support is based on a polydimethyl-acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalising agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexylcarbodiimide/1hydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50 % scavenger mix. Scavengers commonly used are ethandithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesized. Also a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example, Bruckdorfer et al. 2004 and the references as cited therein).

[0112] Trifluoroacetic acid is removed by evaporation *in vacuo*, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilisation of the

aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from e.g. Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.

[0113] Purification may be performed by any one, or a combination of, techniques such as recrystallisation, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e.g. acetonitril/water gradient separation.

[0114] Analysis of peptides may be carried out using thin layer chromatography, electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE), reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF mass spectrometric analysis.

[0115] A further aspect of the invention provides a nucleic acid (for example a polynucleotide) encoding a peptide of the invention. The polynucleotide may be, for example, DNA, cDNA, RNA or combinations thereof, either single- and/or double-stranded. Of course, it is only peptides which contain naturally occurring amino acid residues joined by naturally occurring peptide bonds which are encodable by a polynucleotide. A still further aspect of the invention provides an expression vector expressing a polypeptide according to the invention.

[0116] A variety of methods have been developed to link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

[0117] Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

[0118] A desirable method of modifying the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by (Saiki et al (1988)). This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art. If viral vectors are used, pox- or adenovirus vectors are preferred.

[0119] The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable host to produce a polypeptide comprising the peptide of the invention. Thus, the DNA encoding the peptide of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.

[0120] The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

[0121] Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.

[0122] Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

[0123] Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

[0124] Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus spec.*), plant cells, animal cells and insect cells. Preferably, the system can be mammalian cells such as CHO cells available from the ATCC Cell Biology Collection.

[0125] A typical mammalian cell vector plasmid for constitutive expression comprises the CMV or SV40 promoter with a suitable poly A tail and a resistance marker, such as neomycin. One example is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps). CMV promoter-based vectors (for example from from Sigma-Aldrich) provide transient or

stable expression, cytoplasmic expression or secretion, and N-terminal or C-terminal tagging in various combinations of FLAG, 3xFLAG, c-*myc* or MAT. These fusion proteins allow for detection, purification and analysis of recombinant protein. Dual-tagged fusions provide flexibility in detection.

[0126] The strong human cytomegalovirus (CMV) promoter regulatory region drives constitutive protein expression levels as high as 1 mg/L in COS cells. For less potent cell lines, protein levels are typically ~0.1 mg/L. The presence of the SV40 replication origin will result in high levels of DNA replication in SV40 replication permissive COS cells. CMV vectors, for example, can contain the pMB1 (derivative of pBR322) origin for replication in bacterial cells, the b-lactamase gene for ampicillin resistance selection in bacteria, hGH polyA, and the fl origin. Vectors containing the preprotrypsin leader (PPT) sequence can direct the secretion of FLAG fusion proteins into the culture medium for purification using ANTI-FLAG antibodies, resins, and plates. Other vectors and expression systems are well known in the art for use with a variety of host cells.

[0127] The present invention also relates to an isolated host cell which is not a human embryonic stem cell, transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells may be preferred prokaryotic host cells in some circumstances and typically are a strain of E. coli such as, for example, the E. coli strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and colon cell lines. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors. An overview regarding the choice of suitable host cells for expression can be found in, for example, the textbook of Paulina Balbás and Argelia Lorence "Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols", Part One, Second Edition, ISBN 978-1-58829-262-9, and other literature known to the person of skill.

[0128] Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al (1972) Proc. Natl. Acad. Sci. USA 69, 2110, and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring Harbor, NY. The method of Beggs (1978) Nature 275,104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

[0129] Successfully transformed cells, i.e. cells that contain a DNA construct of the present invention, can be identified by well known techniques such as PCR. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

[0130] It will be appreciated that certain host cells of the invention are useful in the preparation of the peptides of the invention, for example bacterial, yeast and insect cells. However, other host cells may be useful in certain therapeutic methods. For example, antigen-presenting cells, such as dendritic cells, may usefully be used to express the peptides of the invention such that they may be loaded into appropriate MHC molecules. Thus the current invention provides a host cell comprising a nucleic acid or an expression vector according to the invention. In a preferred embodiment the host cell is an antigen presenting cell, in particular a dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein containing prostatic acid phosphatase (PAP) are currently under investigation for the treatment of prostate cancer (Sipuleucel-T) (Small EJ et al 2006; Rini et al 2006)

[0131] A further aspect of the invention provides a method of producing a peptide the method comprising culturing a host cell and isolating the peptide from the host cell or its culture medium.

[0132] In another embodiment the peptide, the nucleic acid or the expression vector of the invention are used in the treatment of cancer. For example, the peptide-may be prepared for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. Preferred methods of peptide injection include s.c., i.d., i.p., i.m., and i.v. Preferred methods of DNA injection include i.d., i.m., s.c., i.p. and i.v. Doses of e.g. between 50 μg and 1.5 mg, preferably 125 μg to 500 μg, of peptide or DNA may be given and will depend on the respective peptide or DNA. Doses of this range were successfully used in previous trials (Brunsvig et al 2006; Staehler et al 2007).

[0133] Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting in vitro T cells with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein

the antigen is a peptide according to the invention. Preferably a sufficient amount of the antigen is used with an antigen-presenting cell.

[0134] In the case of a MHC class II epitope being used as an antigen, the T cells are CD4-positive helper cells, preferably of T_{H1}-type. The MHC class II molecules may be expressed on the surface of any suitable cell. Preferably the cell does not naturally express MHC class II molecules (in which case the cell has been transfected in order to express such a molecule. Alternatively, if the cell naturally expresses MHC class II molecules, it is preferred that it is defective in the antigen-processing or antigen-presenting pathways. In this way, it is possible for the cell expressing the MHC class II molecule to be completely loaded with a chosen peptide antigen before activating the T cell.

[0135] The antigen-presenting cell (or stimulator cell) typically has MHC class II molecules on its surface and preferably is itself substantially incapable of loading said MHC class II molecule with the selected antigen. The MHC class II molecule may readily be loaded with the selected antigen *in vitro*.

[0136] Preferably the mammalian cell lacks or has a reduced level or function of the TAP peptide transporter. Suitable cells that lack the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is the Transporter associated with Antigen Processing.

[0137] The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under Catalogue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre et al 1985.

[0138] Conveniently, said host cell before transfection expresses substantially no MHC class I molecules. It is also preferred if the stimulator cell expresses a molecule important for providing a co-stimulatory signal for T-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The nucleic acid sequences of numerous MHC class II molecules, and of the costimulator molecules are publicly available from the GenBank and EMBL databases.

[0139] Similarly, in case of a MHC class I epitope being used as an antigen, the T cells are CD8-positive CTLs.

[0140] If an antigen-presenting cell is transfected to express such an epitope preferably the cell comprises an expression vector capable of expressing a peptide containing SEQ ID NO 1.

[0141] A number of other methods may be used for generating CTL *in vitro*. For example, the methods described in Peoples et al (1995) and Kawakami et al (1992) use autologous tumor-infiltrating lymphocytes in the generation of CTL. Plebanski et al (1995) makes use of autologous peripheral blood lymphocytes (PLBs) in the preparation of CTL. Jochmus et al (1997) describes the production of autologous CTL by pulsing dendritic cells with peptide or polypeptide, or via infection with recombinant virus. Hill et al (1995) and Jerome et al (1993) make use of B cells in the production of autologous CTL. In addition, macrophages pulsed with peptide or polypeptide, or infected with recombinant virus, may be used in the preparation of autologous CTL. S. Walter et al. 2003 describe the in vitro priming of T cells by using artificial antigen presenting cells (aAPCs), which is also a suitable way for generating T cells against the peptide of choice. In this study, aAPCs were generated by the coupling of preformed MHC:peptide complexes to the surface of polystyrene particles (microbeads) by biotin:streptavidin biochemistry. This system permits the exact control of the MHC density on aAPCs, which allows to selectively elicit high- or low-avidity antigen-specific T cell responses with high efficiency from blood samples. Apart from MHC:peptide complexes, aAPCs should carry other proteins with co-stimulatory activity like anti-CD28 antibodies coupled to their surface. Furthermore such aAPC-based system often require the addition of appropriate soluble factors, e. g. cytokines like interleukin-12.

[0142] Allogeneic cells may also be used in the preparation of T cells and a method is described in detail in WO 97/26328. For example, in addition to Drosophila cells and T2 cells, other cells may be used to present antigens such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target cells. In addition plant viruses may be used (see, for example, Porta et al (1994)) which describes the development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

[0143] The activated T cells that are directed against the peptides of the invention are useful in therapy. Thus, described are activated T cells obtainable by the foregoing methods of the invention.

[0144] Activated T cells, that are produced by the above method will selectively recognise a cell that aberrantly expresses a polypeptide that comprises an amino acid sequence of SEQ ID NO 1 to 10.

[0145] Preferably, the T cell recognizes the cell by interacting through its TCR with the HLA/peptide-complex (for example, binding). The T cells are useful in a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention wherein the patient is administered an effective number of the activated T cells. The T cells that are administered to the patient may be derived from the patient and activated as described above (i.e. they are autologous T cells). Alternatively, the T cells are not from the patient but are from another individual. Of course, it is preferred if the individual is a healthy individual. By "healthy individual" the inventors mean that the individual is generally in good health, preferably has a competent immune system and, more preferably, is not suffering from any disease which can be readily tested for, and detected.

[0146] In vivo, the target cells for the CD4-positive T cells can be cells of the tumor (which sometimes express MHC class II) and/or stromal cells surrounding the tumor (tumor cells) (which sometimes also express MHC class II; (Dengjel et al., 2006)).

[0147] The T cells as described may be used as active ingredients of a therapeutic composition. Thus the invention also describes a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention, the method comprising administering to the patient an effective number of T cells as defined above.

[0148] By "aberrantly expressed" the inventors also mean that the polypeptide is over-expressed compared to normal levels of expression or that the gene is silent in the tissue from which the tumor is derived but in the tumor it is expressed. By "over-expressed" the inventors mean that the polypeptide is present at a level at least 1.2-fold of that present in normal tissue; preferably at least 2-fold, and more preferably at least 5-fold or 10-fold the level present in normal tissue.

[0149] T cells may be obtained by methods known in the art, e.g. those described above.

[0150] Protocols for this so-called adoptive transfer of T cells are well known in the art and can be found, e.g. in (Rosenberg et al., 1987; Rosenberg et al., 1988; Dudley et al., 2002; Yee et al., 2002; Dudley et al., 2005); reviewed in (Gattinoni et al., 2006) and (Morgan et al., 2006).

[0151] Any molecule of the invention, i.e. the peptide, nucleic acid, expression vector or cell is useful for the treatment of disorders, characterised by cells escaping an immune response. Therefore any molecule of the present invention may be used as medicament or in the manufacture of a medicament. The molecule may be used by itself or combined with other molecule(s) of the invention or (a) known molecule(s).

[0152] Preferably, the medicament of the present invention is a vaccine. It may be administered directly into the patient, into the affected organ or systemically i.d., i.m., s.c., i.p. and i.v., or applied ex vivo to cells derived from the patient or a human cell line which are subsequently administered to the patient, or used in vitro to select a subpopulation of immune cells derived from the patient, which are then re-administered to the patient. If the nucleic acid is administered to cells in vitro, it may be useful for the cells to be transfected so as to co-express immune-stimulating cytokines, such as interleukin-2. The peptide may be substantially pure, or combined with an immune-stimulating adjuvant (see below) or used in combination with immune-stimulatory cytokines, or be administered with a suitable delivery system, for example liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole limpet haemocyanin (KLH) or mannan (see WO 95/18145 and Longenecker et al (1993)). The peptide may also be tagged, may be a fusion protein, or may be a hybrid molecule. The peptides whose sequence is given in the present invention are expected to stimulate CD8 T cells. However, stimulation of CD8 CTLs is more efficient in the presence of help provided by CD4 T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 CTL the fusion partner or sections of a hybrid molecule suitably provide epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating epitopes are well known in the art and include those identified in the present invention.

[0153] In one aspect the vaccine comprises at least one peptide, preferably two to 50, more preferably two to 25, even more preferably two to 15 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or thirteen peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I and/or class II molecules.

[0154] The polynucleotide may be substantially pure, or contained in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, RNA or a combination thereof. Methods for designing and introducing such a nucleic acid are well known in the art. An overview is provided by e.g. Pascolo S. 2006; Stan R. 2006, or A Mahdavi 2006. Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing an immune response is not fully understood. Suitable vectors and delivery systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia virus, retroviruses, herpes virus, adeno-associated virus or hybrids containing elements of more than one virus. Non-viral delivery systems include cationic lipids and cationic polymers and are well known in the art of DNA delivery. Physical delivery, such as via a "gene-gun", may also be used. The peptide or peptides encoded by the nucleic acid may be a fusion protein, for example with an epitope that stimulates T cells for the respective opposite CDR as noted above.

[0155] The medicament of the invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or potentiate the immune response (e.g., immune responses mediated by CTLs and helper-T (T_H) cells to an antigen, and would thus be considered useful in the medicament of the present invention. Suitable adjuvants include, but are not limited to, 1018 ISS, aluminium salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod (ALDARA), ImuFact IMP321, Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, JuvImmune, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system, PLG microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred. Several immunological adjuvants (e.g., MF59) specific for dendritic cells and their preparation have been described previously (Dupuis M et al 1998; Allison 1998). Also cytokines may be used. Several cytokines have been directly linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF-α), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF, IL-1 and IL-4)

(U.S. Pat. No. 5,849,589, specifically incorporated herein by reference in its entirety) and acting as immunoadjuvants (e.g., IL-12, IL-15, IL-23, IL-7, IFN-alpha. IFN-beta) (Gabrilovich et al 1996).

[0156] CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting. Without being bound by theory, CpG oligonucleotides act by activating the innate (non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and cellular responses to a wide variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular vaccines and polysaccharide conjugates in both prophylactic and therapeutic vaccines. More importantly it enhances dendritic cell maturation and differentiation, resulting in enhanced activation of T_{H1} cells and strong cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T cell help. The T_{H1} bias induced by TLR9 stimulation is maintained even in the presence of vaccine adjuvants such as alum or incomplete Freund's adjuvant (IFA) that normally promote a T_{H2} bias. CpG oligonucleotides show even greater adjuvant activity when formulated or co-administered with other adjuvants or in formulations such as microparticles, nanoparticles, lipid emulsions or similar formulations, which are especially necessary for inducing a strong response when the antigen is relatively weak. They also accelerate the immune response and enable the antigen doses to be reduced by approximately two orders of magnitude, with comparable antibody responses to the full-dose vaccine without CpG in some experiments (Krieg et al 2006). US Pat. No. 6,406,705 B1 describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. A CpG TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen (Berlin, Germany) which is a preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

[0157] Other examples for useful adjuvants include, but are not limited to chemically modified CpGs (e.g. CpR, Idera), dsRNA analogues such as Poly(I:C) and AmpliGen, non-CpG bacterial DNA or RNA as well as immunoactive small molecules and antibodies such as cyclophosphamide, sunitinib, Bevacizumab, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4 and SC58175, which may act therapeutically and/or as an adjuvant. The amounts and concentrations of adjuvants and additives useful in the context of the present invention can readily be determined by the skilled artisan without undue experimentation. Preferred adjuvants are dSLIM, Interferon-alpha, -beta, CpG7909, IC31, , ALDARA (Imiquimod), PeviTer, RNA, tadalafil, temozolomide, and JuvImmune.

[0158] The present invention provides a medicament that is useful in treating cancer, in particular neuronal cancer, in particular brain cancer. The cancer may be non-metastatic or metastatic, in particular it may be astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET, e.g. medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma), tumors of the pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin (e.g. gliomatosis cerebri, astroblastoma) or glioblastoma.

[0159] Since the peptides of the invention were isolated from glioblastoma, the medicament of the invention is preferably used to treat glioblastoma.

[0160] The present invention will now be described in the following examples that describe preferred embodiments thereof, nevertheless, without being limited thereto.

EXAMPLES

EXAMPLE 1:

Identification of tumor associated peptides (TUMAPs) presented on cell surface

Tissue samples

[0161] Patients' tumor and healthy tissues were provided by Hôpital Cantonal Universitaire de Genève (Medical Oncology Laboratory of Tumor Immunology) and Neurochirurgische Universitäts-Klinik Heidelberg (Molekularbiologisches Labor). Written informed consents of all patients had been given before surgery. Tissues were shock-frozen in liquid nitrogen immediately after surgery and stored until isolation of TUMAPs at -80°C.

Isolation of HLA peptides from tissue samples

[0162] HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to a slightly modified protocol (Falk, K. et al 1991; Seeger, F.H. et al. T 1999) using the HLA-A*02-specific antibody BB7.2 or the HLA-A, -B, -C-specific antibody W6/32, CNBr-activated sepharose, acid treatment, and ultrafil-

tration.

Detection of TUMAPs by ESI-liquid chromatography mass spectrometry (ESI-LCMS)

Method one:

[0163] The obtained HLA peptide pools were separated according to their hydrophobicity by reversed-phase chromatography (CapLC, Waters) and the eluting peptides were analyzed in a hybrid quadrupole orthogonal acceleration time of flight tandem mass spectrometer (Q-TOF Ultima, Waters) equipped with an ESI source. Peptide pools were loaded onto a C18 pre-column for concentration and desalting. After loading, the pre-column was placed in line for separation by a fused-silica micro-capillary column (75 μm i.d. x 250 mm) packed with 5 μm C18 reversed-phase material (Dionex). Solvent A was 4 mM ammonium acetate/water. Solvent B was 2 mM ammonium acetate in 80% acetonitrile/water. Both solvents were adjusted to pH 3.0 with formic acid. A binary gradient of 15% to 60% B within 90 minutes was performed, applying a flow rate of 5 μl/min reduced to approximately 200 nl/min by a split-system. A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the micro-ESI source. The integration time for the TOF analyzer was 1.9 s with an interscan delay of 0.1 s. Subsequently, the peptide sequences were revealed by collisionally induced decay (CID) mass spectrometry (ESI-LCMS/MS). The identified TUMAP sequence was assured by comparison of the generated natural TUMAP fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide.

Method two:

[0164] The HLA peptide pools as obtained were separated according to their hydrophobicity by reversed-phase chromatography (Acquity UPLC system, Waters) and the eluting peptides were analyzed in an LTQ- Orbitrap hybrid mass spectrometer (ThermoElectron) equipped with an ESI source. Peptide pools were loaded directly onto the analytical fused-silica micro-capillary column (75 μm i.d. x 250 mm) packed with 1.7 μm C18 reversed-phase material (Waters) applying a flow rate of 400 nL per minute. Subsequently, the peptides were separated using an two-step 180 minute-binary gradient from 10% to 33% B at flow rates of 300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the micro-ESI source. The LTQ-Orbitrap mass spectrometer was operated in the data-dependent mode using a TOP5 strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the orbitrap (R = 30 000), which was followed by MS/MS scans also in the orbitrap (R = 7500) on the 5 most abundant precursor ions with dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted by SEQUEST and additional manual control. The identified TUMAP sequence was assured by comparison of the generated natural TUMAP fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide. Figs. 1a and b show exemplary spectra obtained from tumor tissue for MHC class I associated TUMAPs.

Table 3: List of tumor samples on which the peptides were identified

SEQ ID NO	Peptide Code	Tumor Sources
1	PTP-001	GB1006T,GB1012T
2	PTP-002	GB1023T,GB6003T
3	PTP-003	GB1012T,GB1014T,GB1020T,GB1021T,GB1023T,GB1026T,GB6003T,GB6010T, GB6015T,GB6016T,GB6019T
4	PTP-004	GB1023T,GB6010T
5	PTP-005	GB6010T
6	PTP-006	GB1012T
7	PTP-007	GB1023T,GB6010T
8	PTP-008	NCH361T
9	PTP-009	GB6003T
10	PTP-010	GB6010T

EXAMPLE 2

Expression profiling of genes encoding the peptide of the invention

[0165] Not all peptides identified as being presented on the surface of tumor cells by MHC molecules are suitable for immunotherapy, because the majority of these peptides are derived from normal cellular proteins expressed by many cell types. Only few of these peptides are tumor-associated and likely able to induce T cells with a high specificity of recognition for the tumor from which they were derived. In order to identify such peptides and minimize the risk for autoimmunity induced by vaccination the inventors focused on those peptides that are derived from proteins that are over-expressed on tumor cells compared to the majority of normal tissues.

[0166] The ideal peptide will be derived from a protein that is unique to the tumor and not present in any other tissue. To identify peptides that are derived from genes with an expression profile similar to the ideal one the identified peptides were assigned to the proteins and genes, respectively, from which they were derived and expression profiles of these genes were generated.

RNA sources and preparation

[0167] Surgically removed tissue specimens were provided by two different clinical sites (see Example 1) after written informed consent had been obtained from each patient. Tumor tissue specimens were snap-frozen in liquid nitrogen immediately after surgery and later homogenized with mortar and pestle under liquid nitrogen. Total RNA was prepared from these samples using TRIzol (Invitrogen, Karlsruhe, Germany) followed by a cleanup with RNeasy (QIAGEN, Hilden, Germany); both methods were performed according to the manufacturer's protocol.

[0168] Total RNA from healthy human tissues was obtained commercially (Ambion, Huntingdon, UK; Clontech, Heidelberg, Germany; Stratagene, Amsterdam, Netherlands; BioChain, Hayward, CA, USA). The RNA from several individuals (between 2 and 123 individuals) was mixed such that RNA from each individual was equally weighted. Leukocytes were isolated from blood samples of 4 healthy volunteers.

[0169] Quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

Microarray experiments

[0170] Gene expression analysis of all tumor and normal tissue RNA samples was performed by Affymetrix Human Genome (HG) U133A or HG-U133 Plus 2.0 oligonucleotide microarrays (Affymetrix, Santa Clara, CA, USA). All steps were carried out according to the Affymetrix manual (http://www.affymetrix.com/support/technical/manual/expression_manual.affx). Briefly, double-stranded cDNA was synthesized from 5-8 μg of total RNA, using SuperScript RTII (Invitrogen) and the oligo-dT-T7 primer (MWG Biotech, Ebersberg, Germany) as described in the manual. In vitro transcription was performed with the BioArray High Yield RNA Transcript Labelling Kit (ENZO Diagnostics, Inc., Farmingdale, NY, USA) for the U133A arrays or with the GeneChip IVT Labelling Kit (Affymetrix) for the U133 Plus 2.0 arrays, followed by cRNA fragmentation, hybridization, and staining with streptavidin-phycoerythrin and biotinylated anti-streptavidin antibody (Molecular Probes, Leiden, Netherlands). Images were scanned with the Agilent 2500A GeneArray Scanner (U133A) or the Affymetrix Gene-Chip Scanner 3000 (U133 Plus 2.0), and data were analysed with the GCOS software (Affymetrix), using default settings for all parameters. For normalisation, 100 housekeeping genes provided by Affymetrix were used (http://www.affymetrix.com/support/technical/mask_files.affx). Relative expression values were calculated from the signal log ratios given by the software and the normal sample was arbitrarily set to 1.0.

[0171] The expression profile of the source gene of the peptide of the present invention (PTPRZ1) shows a high expression in glioblastoma tumor tissue whereas the gene is not expressed or expressed at very low levels in normal tissues (Fig. 2).

EXAMPLE 3

In vitro immunogenicity of MHC class I presented peptides

In vitro priming of CD8+ T cells

[0172] In order to perform *in vitro* stimulations by artificial antigen presenting cells (aAPC) loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, the inventors first isolated PBMCs (peripheral blood mononuclear cells) from fresh HLA-A*02+ buffy coats by using standard density gradient separation medium (PAA, Cölbe, Germany). Buffy coats were obtained from the Katharinenhospital Stuttgart. Isolated PBMCs were incubated overnight in T-cell medium (TCM)

for human *in vitro* priming consisting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAA, Cölbe, Germany), 100 U/ml Penicillin / 100 μg/ml Streptomycin (Cambrex, Verviers, Belgium), 1 mM sodium pyruvate (CC Pro, Neustadt, Germany) and 20 μg/ml Gentamycin (Cambrex,). CD8+ lymphocytes were isolated using the CD8+ MACS positive selection kit (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Obtained CD8+ T cells were incubated until use in TCM supplemented with 2.5 ng/ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Chiron, Munich, Gemany). Generation of pMHC/anti-CD28 coated beads, T-cell stimulations and readout was performed as described before (Walter et al., 2003) with minor modifications. Briefly, biotinylated recombinant HLA-A*0201 molecules lacking the transmembrane domain and being biotinylated at the carboxy terminus of the heavy chain were produced following a method described by (Altman et al., 1996). The purified costimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung et al., 1987) was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.60 μm large streptavidin coated polystyrene particles (Bangs Laboratories, Illinois/USA). pMHC used as positive and negative controls were A*0201/MLA-001 (peptide ELAGIGILTV from modified Melan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5), respectively.

[0173] 800.000 beads / 200 μl were coated in 96-well plates in the presence of 600 ng biotin anti-CD28 plus 200 ng relevant biotin-pMHC (high density beads) or 2 ng relevant plus 200 ng irrelevant (pMHC library) MHC (low density beads). Stimulations were initiated in 96-well plates by conincubating $1x10^6$ CD8+ T cells with $2x10^5$ washed coated beads in 200 μl TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3-4 days at 37°C. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubating was continued for 3-4 days at 37°C. This stimulation cycle was performed for a total of three times. Finally, tetrameric analyses were performed with fluorescent MHC tetramers (produced as described by (Altman et al., 1996)) plus antibody CD8-FITC clone SK1 (BD, Heidelberg, Germany) on a FACSCalibur or a LSR II flow cytometer (BD). Peptide specific cells were calculated as percentage of total CD8+ T cells. Evaluation of tetrameric analysis was done using the software FCS Express (De Novo Software). In vitro priming of specific tetramer+ CD8+ lymphocytes was detected by appropriate gating and by comparing to negative control stimulations. Immunogenicity for a given antigen was detected if at least one evaluable in vitro stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after in vitro stimulation (i.e. this well contained at least 1% of specific tetramer+ among CD8+ T cells and the percentage of specific tetramer+ cells was at least 10x the median of the negative control stimulations).

[0174] A representative staining showing generation of T-cell lines specific for PTP-002 and PTP-001 is shown in Figure 3. The results are summarized in table 4, below.

Table 4: In vitro immunogenicity of peptides, PTP-001 is of the invention

Antigen	Immunogenicity detected	Positive donors / donors tested	Positive wells / wells tested
PTP-001	yes	6 / 6 (100%)	33 / 96 (34 %)
PTP-002	Yess	2 / 4 (50%)	8 / 48 (17%)

[0175] Results of *in vitro* immunogenicity experiments as conducted by the inventors and the applicant immatics showing the percentage of positive tested donors and wells are summarized here. Results shown have been obtained by stimulation of CD8+ cells with high density beads. As different human serum lots may highly affect the immunogenicity results, only assays in which one and the same serum lot was used, were evaluated together.

List of references as cited

[0176]

Allison AC 1998; The mode of action of immunological adjuvants; Dev Biol Stand.; 92:3-11.

Altman JD, Moss PA, Goulder PJ, Barouch DH, Heyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996). Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96.

Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P (2006). Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur. J Immunol. 36, 1805-1814.

Ariyama T, Hasegawa K, Inazawa J, Mizuno K, Ogimoto M, Katagiri T, Yakura H (1995). Assignment of the human protein tyrosine phosphatase, receptor-type, zeta (PTPRZ) gene to chromosome band 7q31.3. Cytogenet. Cell

Genet. 70, 52-54.

Barnea G, Silvennoinen O, Shaanan B, Honegger AM, Canoll PD, D'Eustachio P, Morse B, Levy JB, Laforgia S, Huebner K, . (1993). Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. Mol. Cell Biol. 13, 1497-1506.

Boyton RJ, Lohmann T, Londei M, Kalbacher H, Halder T, Frater AJ, Douek DC, Leslie DG, Flavell RA, Altmann DM (1998). Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Int. Immunol. 10, 1765-1776.

Bruckdorfer T, Marder O, Albericio F.(2004) From production of peptides in milligram amounts for research to multi-ton quantities for drugs of the future Curr Pharm Biotechnol. Feb; 5(1):29-43

Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006); Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer; Cancer Immunol Immunother.; 55(12):1553-1564

Burton EC, Prados MD (2000). Malignant gliomas. Curr. Treat. Options. Oncol 1, 459-468.

CBTRUS. Primary Brain Tumors in the United States, Statistical Report. 2006. Ref Type: Internet Communication

Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ (1993). T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Ann N. Y. Acad. Sci. 690, 101-112.

Colombetti S, Basso V, Mueller DL, Mondino A (2006). Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol. 176, 2730-2738.

Cresswell P (1994). Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12, 259-293.

Dazzi C, Cariello A, Giannini M, Del DM, Giovanis P, Fiorentini G, Leoni M, Rosti G, Turci D, Tienghi A, Vertogen B, Zumaglini F, De GU, Marangolo M (2000). A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study. Anticancer Res. 20, 515-518.

Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanovic S (2006). Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. Clin Cancer Res. 12, 4163-4170.

Dix AR, Brooks WH, Roszman TL, Morford LA (1999). Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 100, 216-232.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854. -

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357.

Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, McDonald DM (1998); Dendritic cells internalize vaccine adjuvant after intramuscular injection; Cell Immunol.; 186(1):18-27

Falk,K., Rotzschke,O., Stevanovic,S., Jung,G. & Rammensee,H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991)

Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001a). Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259.

Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001b). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A 98, 8809-8814.

Gabrilovich DI, Cunningham HT, Carbone DP; IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer; J Immunother Emphasis Tumor Immunol. 1996 (6):414-418

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.

Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP (2006). Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393.

Gebbink MF, van E, I, Hateboer G, Suijkerbuijk R, Beijersbergen RL, Geurts van KA, Moolenaar WH (1991). Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. FEBS Lett. 290, 123-130.

Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ (2003). Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl. Acad. Sci. U. S. A 100, 8862-8867.

Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F (1995). Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp. Med 181, 1847-1855.

Hanada K, Yewdell JW, Yang JC (2004). Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252-256.

Harroch S, Furtado GC, Brueck W, Rosenbluth J, Lafaille J, Chao M, Buxbaum JD, Schlessinger J (2002). A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat. Genet. 32, 411-414.

Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner DD, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No. 18S (June 20 Supplement), 2006: 2529. 6-20-2006.

Hill et al (1995) J. Exp. Med. 181, 2221-2228

Jerome et al (1993) J. Immunol. 151, 1654-1662

Jochmus et al (1997) J. Gen. Virol. 78, 1689-1695

Jung G, Ledbetter JA, Muller-Eberhard HJ (1987). Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci U S A 84, 4611-4615.

Kaplan R, Morse B, Huebner K, Croce C, Howk R, Ravera M, Ricca G, Jaye M, Schlessinger J (1990). Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. Proc Natl. Acad. Sci. U. S. A 87, 7000-7004.

Karre and Ljunggren (1985) J. Exp. Med. 162, 1745

Kawakami et al (1992) J. Immunol. 148, 638-643

Kennedy RC, Shearer MH, Watts AM, Bright RK (2003). CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res. 63, 1040-1045.

Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borras-Cuesta F, Celis E (2002). Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res. 8, 3219-3225.

Arthur M. Krieg, Therapeutic potential of Toll-like receptor 9 activation 2006, Nature Reviews, Drug Discovery, 5, JUNE, 471-484

Krueger NX, Streuli M, Saito H (1990). Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J 9, 3241-3252.

Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, Rammensee HG, Stevanovic S (2004). Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22, 450-454.

Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang JT, Cannizzaro LA, Park SH, Druck T,. (1993). The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J Biol. Chem. 268, 10573-10581.

Longenecker et al (1993) Ann. NY Acad. Sci. 690,276-291

Lu et al (1981) J. Org. Chem. 46, 3433

Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS (2005). Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 280, 26953-26964.

Macdonald DR (2001). Temozolomide for recurrent high-grade glioma. Semin. Oncol 28, 3-12.

Mach B, Steimle V, Martinez-Soria E, Reith W (1996). Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14, 301-331.

A Mahdavi and BJ Monk Recent advances in human papillomavirus vaccines Curr Oncol Rep 2006, 6, 465-472.

Malcherek G, Gnau V, Stevanovic S, Rammensee HG, Jung G, Melms A (1994). Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J Immunol. 153, 1141-1149.

Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999). Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp. Med 189, 871-876.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science.

Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J, Jones TA, Babbage JW, Vatcheva R, Ichimura K, East P, Poullikas C, Collins VP, Carter NP, Tomlinson IP, Sheer D (2006). Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle 5, 783-791.

Strubin, M., Mach, B. and Long, E.O. (1984) The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity EMBO J. 3 (4), 869-872.

Napolitano M, Keime-Guibert F, Monjour A, Lafitte C, Ameri A, Cornu P, Broet P, Delattre JY (1999). Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. J Neurooncol. 45, 229-235.

Nieder C, Grosu AL, Molls M (2000). A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev. 26, 397-409.

Novellino L, Castelli C, Parmiani G (2005). A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54, 187-207.

Pascolo S. 2006: Vaccination with messenger RNA Methods Mol Med, 127; 23-40

Peoples et al (1995) Proc. Natl. Acad. Sci. USA 92,432-436

Perez-Pinera P, Garcia-Suarez O, Menendez-Rodriguez P, Mortimer J, Chang Y, Astudillo A, Deuel TF (2007). The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 362, 5-10.

Plebanski et al (1995) Eur. J. Immunol. 25, 1783-1787

Porta et al (1994) Virology 202, 449-955

Prados MD, Levin V (2000). Biology and treatment of malignant glioma. Semin. Oncol 27, 1-10.

Qin Z, Blankenstein T (2000). CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 12, 677-686.

Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003). A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63, 4095-4100.

Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219.

Rammensee,H.G., Bachmann,J., and Stevanovic,S. (1997). MHC Ligands and Peptide Motifs. Springer-Verlag, Heidelberg, Germany).

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ (2006); Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy; Cancer.; 107(1):67-74)

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT,. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.

Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA,. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J Med 319, 1676-1680.

Roth W, Weller M (1999). Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol. Life Sci. 56, 481-506.

Sablotzki A, Ebel H, Muhling J, Dehne MG, Nopens H, Giesselmann H, Hempelmann G (2000). Dysregulation of immune response following neurosurgical operations. Acta Anaesthesiol. Scand. 44, 82-87.

Saiki et al (1988) Science 239,487-491

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. (2006); Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer; J Clin Oncol.; 24(19):3089-3094

Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774.

Seeger,F.H. et al. 1999 The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. Immunogenetics 49, 571-576.

Shedlock DJ, Shen H (2003). Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339.

Singh-Jasuja H, Emmerich NP, Rammensee HG (2004). The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53, 187-195.

M. Staehler, A. Stenzl, P. Y. Dietrich, T. Eisen, A. Haferkamp, J. Beck, A. Mayer, S. Walter, H. Singh, J. Frisch, C. G. Stief (2008); An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901, ASCO meeting 2007; Abstract No 3017

R. Stan, JD Wolchok and AD Cohen DNA vaccines against cancer Hematol Oncol Clin North Am 2006, 3; 613-636

Sun JC, Bevan MJ (2003). Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342.

Sylvester-Hvid C, Kristensen N, Blicher T, Ferre H, Lauemoller SL, Wolf XA, Lamberth K, Nissen MH, Pedersen LO, Buus S (2002). Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens 59, 251-258.

Tompkins SM, Rota PA, Moore JC, Jensen PE (1993). A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. J Immunol. Methods 163, 209-216.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De PE, Van den EB, Knuth A, Boon T (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.

Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der BP, Boon T, Van Den Eynde BJ (2004). An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587-590.

Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, Martin R (1994). Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol. 153, 1665-1673.

Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring HJ, Rammensee HG, Stevanovic S (2003). Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J. Immunol. 171, 4974-4978.

Wang JC, Livingstone AM (2003). Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol. 171, 6339-6343.

Wang V, Davis DA, Haque M, Huang LE, Yarchoan R (2005). Differential gene up-regulation by hypoxia-inducible factor-lalpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 65, 3299-3306.

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG (2002). Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818-5827.

Wu CW, !Lost Data, Li AF, Chi CW, Lin WC (2006). Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett. 242, 95-103.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A 99, 16168-16173.

Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997). Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57, 4570-4577.

Zeh HJ, III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999). High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 162, 989-994.

SEQUENCE LISTING

[0177]

<110> immatics biotechnologies GmbH

<120> Novel immunotherapy against Neuronal and Brain Tumors

<130> FB19941

<160> 10

<170> PatentIn version 3.5

<210> 1
<211> 9
<212> PRT
<213> Homo sapiens

<400> 1

Ala Leu Thr Thr Leu Met His Gln Leu
1 5

<210> 2
<211> 9
<212> PRT
<213> Homo sapiens

<400> 2

Phe Leu Tyr Lys Val Ile Leu Ser Leu
1 5

<210> 3
<211> 9
<212> PRT
<213> Homo sapiens

<400> 3

Ala Ile Ile Asp Gly Val Glu Ser Val
1 5

<210> 4
<211> 9
<212> PRT
<213> Homo sapiens

<400> 4

Phe Leu Leu Pro Asp Thr Asp Gly Leu
1 5

<210> 5
<211> 9
<212> PRT
<213> Homo sapiens

<400> 5

Lys Val Phe Ala Gly Ile Pro Thr Val
1 5

<210> 6
<211> 9
<212> PRT
<213> Homo sapiens

<400> 6

Gln Gln Ser Asp Tyr Ser Ala Ala Leu
1 5

<210> 7
<211> 9
<212> PRT
<213> Homo sapiens

<400> 7

Thr Gln Asp Asp Tyr Val Leu Glu Val
1 5

<210> 8
<211> 9
<212> PRT
<213> Homo sapiens

<400> 8

Gln His Glu Gly Thr Val Asn Ile Phe
1 5

<210> 9
<211> 12
<212> PRT
<213> Homo sapiens

<400> 9

Ser Val Phe Gly Asp Asp Asn Lys Ala Leu Ser Lys
1 5 10

<210> 10
<211> 14
<212> PRT

<213> Homo sapiens

<400> 10

```
Glu Ile Gly Trp Ser Tyr Thr Gly Ala Leu Asn Gln Lys Asn
1               5                  10
```

Claims

1. A peptide consisting of the amino acid sequence according to SEQ ID No. 1.

2. The peptide according to claim 1, wherein said peptide is part of a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

3. A nucleic acid, encoding for the peptide according to claim 1 or 2.

4. An expression vector expressing the nucleic acid according to claim 3.

5. The peptide according to claim 1 or 2, the nucleic acid according to claim 3 or the expression vector according to claim 4 for use in medicine.

6. An isolated host cell which is not a human embryonic stem cell, comprising the nucleic acid according to claim 3 or the expression vector according to claim 4, wherein said host cell preferably is an antigen presenting cell, in particular a dendritic cell.

7. A method of producing a peptide according to claim 1 or 2, the method comprising culturing the host cell according to claim 6 that expresses the nucleic acid according to claim 3 or the expression vector according to claim 4, and isolating the peptide from the host cell or its culture medium.

8. An *in vitro* method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting *in vitro* CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide according to claim 1.

9. The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use in the treatment of cancer.

10. The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use in the manufacture of a medicament against cancer.

11. The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use according to claim 10, wherein said medicament is a vaccine.

12. The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use according to claim 10 or 11, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuro-blastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET), medulloblastoma, medulloepithelioma, neuro-blastoma, retinoblastoma, ependymoblastoma, tumors of the pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin, gliomatosis cerebri, astroblastoma or glioblastoma.

Patentansprüche

1. Peptid, bestehend aus der Aminosäuresequenz nach SEQ ID No. 1.

2. Peptid nach Anspruch 1, wobei das Peptid Teil eines Fusionsproteins ist, umfassend N-terminale Aminosäuren der HLA-DR Antigen-assoziierten invarianten Kette (Ii).

3. Nukleinsäure, die für das Peptid nach Anspruch 1 oder 2 kodiert.

4. Expressionsvektor der die Nukleinsäure nach Anspruch 3 exprimiert.

5. Peptid nach Anspruch 1 oder 2, Nukleinsäure nach Anspruch 3 oder Expressionsvektor nach Anspruch 4 zur Verwendung in der Medizin.

6. Isolierte Wirtszelle, die keine menschliche embryonale Stammzelle ist, umfassend die Nukleinsäure nach Anspruch 3 oder den Expressionsvektor nach Anspruch 4, wobei die Wirtszelle bevorzugt eine Antigen-präsentierende Zelle ist, insbesondere eine dendritische Zelle.

7. Verfahren zur Herstellung eines Peptids nach Anspruch 1 oder 2, wobei das Verfahren ein Kultivieren der Wirtszelle nach Anspruch 6 umfasst, die die Nukleinsäure nach Anspruch 3 oder den Expressionsvektor nach Anspruch 4 exprimiert, und Isolieren des Peptids von der Wirtszelle oder ihres Kulturmediums.

8. *In vitro* Verfahren zur Herstellung von aktivierten zytotoxischen T Lymphozyten (CTL), wobei das Verfahren ein in Kontakt bringen *in vitro* von CTL mit Antigen-beladenen menschlichen Klasse I MHC Molekülen umfasst, die auf der Oberfläche einer geeigneten Antigen-präsentierenden Zelle oder eines künstlichen Konstrukts, das eine Antigen-präsentierende Zelle nachahmt, exprimiert werden für eine Zeitdauer, die ausreichend ist, um die CTL auf eine Antigen-spezifische Weise zu aktivieren, wobei das Antigen das Peptid nach Anspruch 1 ist.

9. Peptid nach Anspruch 1 oder 2, Nukleinsäure nach Anspruch 3, Expressionsvektor nach Anspruch 4, oder Zelle nach Anspruch 6 zur Verwendung in der Behandlung von Krebs.

10. Peptid nach Anspruch 1 oder 2, Nukleinsäure nach Anspruch 3, Expressionsvektor nach Anspruch 4, oder Zelle nach Anspruch 6 zur Verwendung in der Herstellung eines Medikaments gegen Krebs.

11. Peptid nach Anspruch 1 oder 2, Nukleinsäure nach Anspruch 3, Expressionsvektor nach Anspruch 4, oder Zelle nach Anspruch 6 zur Verwendung nach Anspruch 10, wobei das Medikament ein Vakzin ist.

12. Peptid nach Anspruch 1 oder 2, Nukleinsäure nach Anspruch 3, Expressionsvektor nach Anspruch 4, oder Zelle nach Anspruch 6 zur Verwendung nach Anspruch 10 oder 11, wobei der Krebs ausgewählt ist aus Astrocytom, pilocytischem Astrocytom, dysembryoplastischem neuroepithelialem Tumor, Oligodendrogliomen, Ependymom, Glioblastoma multiforme, gemischten Gliomen, Oligoastrocytomen, Medulloblastom, Retinoblastom, Neuroblastom, Germinom, Teratom, Gangliogliomen, Gangliocytom, zentralem Gangliocytom, primitiven neuroectodermalen Tumoren (PNET), Medulloblastom, Medulloepitheliom, Neuroblastom, Retinoblastom, Ependymoblastoma, Tumoren der pinealen Parenchyme (z.B. Pineocytom, Pineoblastom), ependymalen Zelltumoren, choroid Plexus Tumoren, neuroepithelialen Tumoren unbestimmten Ursprungs, Gliomatosis cerebri, Astroblastom oder Glioblastom.

Revendications

1. Peptide consistant en la séquence d'acides aminés correspondant à la séquence SEQ ID n° 1.

2. Peptide conforme à la revendication 1, où ledit peptide fait partie d'une protéine de fusion comprenant des acides aminés N-terminaux de la chaîne invariante (Ii) associée aux antigènes du système HLA-DR.

3. Acide nucléique, codant pour le peptide conforme à la revendication 1 ou 2.

4. Vecteur d'expression exprimant l'acide nucléique conforme à la revendication 3.

5. Peptide conforme à la revendication 1 ou 2, acide nucléique conforme à la revendication 3 ou vecteur d'expression conforme à la revendication 4 pour usage médical.

6. Cellule hôte isolée qui n'est pas une cellule souche embryonnaire humaine, comprenant l'acide nucléique conforme

à la revendication 3 ou le vecteur d'expression conforme à la revendication 4, où ladite cellule hôte est de préférence une cellule présentatrice d'antigènes, en particulier une cellule dendritique.

7. Méthode de production d'un peptide conforme à la revendication 1 ou 2, cette méthode comprenant la mise en culture de la cellule hôte conforme à la revendication 6 qui exprime l'acide nucléique conforme à la revendication 3 ou le vecteur d'expression conforme à la revendication 4, et l'isolement du peptide de la cellule hôte ou de son milieu de culture.

8. Méthode *in vitro* de production de lymphocytes T cytotoxiques (CTL) activés, cette méthode comprenant la mise en contact *in vitro* des CTL avec des molécules du CMH de classe I humain chargées d'antigènes exprimées à la surface d'une cellule présentatrice d'antigènes appropriée ou d'une construction artificielle imitant une cellule présentatrice d'antigènes pendant un temps suffisant pour activer, de manière antigène-spécifique, lesdits CTL, où ledit antigène est le peptide conforme à la revendication 1.

9. Peptide conforme à la revendication 1 ou 2, acide nucléique conforme à la revendication 3, vecteur d'expression conforme à la revendication 4, ou cellule conforme à la revendication 6 pour utilisation dans le traitement du cancer.

10. Peptide conforme à la revendication 1 ou 2, acide nucléique conforme à la revendication 3, vecteur d'expression conforme à la revendication 4, ou cellule conforme à la revendication 6 pour utilisation dans la fabrication d'un médicament contre le cancer.

11. Peptide conforme à la revendication 1 ou 2, acide nucléique conforme à la revendication 3, vecteur d'expression conforme à la revendication 4, ou cellule conforme à la revendication 6 pour utilisation conformément à la revendication 10, où ledit médicament est un vaccin.

12. Peptide conforme à la revendication 1 ou 2, acide nucléique conforme à la revendication 3, vecteur d'expression conforme à la revendication 4, ou cellule conforme à la revendication 6 pour utilisation conformément à la revendication 10 ou 11, où ledit cancer est sélectionné parmi astrocytome, astrocytome pilocytique, tumeur neuroépithéliale dysembryoplasique, oligodendrogliomes, épendymome, glioblastome multiforme, gliomes mixtes, oligoastrocytomes, médulloblastome, rétinoblastome, neuroblastome, germinome, tératome, gangliogliomes, ganglioneurome, ganglioneurome du système nerveux central, tumeurs neuro-ectodermiques primitives (TNEP), médulloblastome, médullo-épithéliome, neuroblastome, rétinoblastome, épendymoblastome, tumeurs du parenchyme pinéal (par ex. pinéocytome, pinéoblastome), tumeurs dérivées des cellules épendymaires, tumeurs du plexus choroïde, tumeurs neuroépithéliales d'origine incertaine, gliomatose du cerveau, astroblastome ou glioblastome.

Fig. 1a: PTP-001 (GB1006)



Fig. 1b: PTP-002 (GB6003)





Fig. 2: mRNA Expression profile of PTPRZ1

Fig. 3


A*0201 / Neg. control peptide
HD
A*0201 / PTP-001
HD
0,41%
0,03%
0,36%
4,52%
A*0201 / Neg. control peptide
A*0201 / PTP-001
A*0201 / Neg. control peptide
HD
A*0201 / PTP-002
HD
0,01%
11,58%
4,30%
0,04%
A*0201 / PTP-002
A*0201 / Neg. control peptide

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- FR 2000 **[0004]**
- WO 2005116051 A **[0010]**
- WO 2007028574 A **[0050]**
- EP 1760088 B1, Dengjel **[0050]**
- US 6455026 B **[0079]**
- US 7060275 B2 **[0081]**
- US 4897445 A **[0098]**
- US 4440859 A **[0119]**
- US 4530901 A **[0119]**
- US 4582800 A **[0119]**
- US 4677063 A **[0119]**
- US 4678751 A **[0119]**
- US 4704362 A **[0119]**
- US 4710463 A **[0119]**
- US 4757006 A **[0119]**
- US 4766075 A **[0119]**
- US 4810648 A **[0119]**
- WO 9726328 A **[0142]**
- WO 9518145 A, Longenecker **[0152]**
- US 5849589 A **[0155]**
- US 6406705 B1, Krieg **[0156]**

Non-patent literature cited in the description

- *Neurol. Med. Chir. (Tokyo),* 1994, vol. 34, 91-94 **[0005]**
- *Neurol. Med. Chir. (Tokyo),* 1993, vol. 33, 425-458 **[0005]**
- *Neuropathology,* 1997, vol. 17, 186-188 **[0005]**
- **MEZIERE et al.** *J. Immunol.,* 1997, vol. 159, 3230-3237 **[0097]**
- Current Protocols In Protein Science. John Wiley & Sons, 1995 **[0101]**
- **PAULINA BALBÁS ; ARGELIA LORENCE.** Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols **[0127]**
- **COHEN et al.** *Proc. Natl. Acad. Sci. USA,* 1972, vol. 69, 2110 **[0128]**
- **SAMBROOK et al.** Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory, 1989 **[0128]**
- **SHERMAN et al.** Methods In Yeast Genetics, A Laboratory Manual. Cold Spring Harbor **[0128]**
- **BEGGS.** *Nature,* 1978, vol. 275, 104-109 **[0128]**
- **ALLISON AC.** The mode of action of immunological adjuvants. *Dev Biol Stand.,* 1998, vol. 92, 3-11 **[0176]**
- **ALTMAN JD ; MOSS PA ; GOULDER PJ ; BAROUCH DH ; HEYZER-WILLIAMS MG ; BELL JI ; MCMICHAEL AJ ; DAVIS MM.** Phenotypic analysis of antigen-specific T lymphocytes. *Science,* 1996, vol. 274, 94-96 **[0176]**
- **APPAY V ; SPEISER DE ; RUFER N ; REYNARD S ; BARBEY C ; CEROTTINI JC ; LEYVRAZ S ; PINILLA C ; ROMERO P.** Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. *Eur. J Immunol.,* 2006, vol. 36, 1805-1814 **[0176]**
- **ARIYAMA T ; HASEGAWA K ; INAZAWA J ; MIZUNO K ; OGIMOTO M ; KATAGIRI T ; YAKURA H.** Assignment of the human protein tyrosine phosphatase, receptor-type, zeta (PTPRZ) gene to chromosome band 7q31.3. *Cytogenet. Cell Genet.,* 1995, vol. 70, 52-54 **[0176]**
- **BARNEA G ; SILVENNOINEN O ; SHAANAN B ; HONEGGER AM ; CANOLL PD ; D'EUSTACHIO P ; MORSE B ; LEVY JB ; LAFORGIA S ; HUEBNER K.** Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. *Mol. Cell Biol.,* 1993, vol. 13, 1497-1506 **[0176]**
- **BOYTON RJ ; LOHMANN T ; LONDEI M ; KALBACHER H ; HALDER T ; FRATER AJ ; DOUEK DC ; LESLIE DG ; FLAVELL RA ; ALTMANN DM.** Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. *Int. Immunol.,* 1998, vol. 10, 1765-1776 **[0176]**
- **BRUCKDORFER T ; MARDER O ; ALBERICIO F.** From production of peptides in milligram amounts for research to multi-ton quantities for drugs of the future. *Curr Pharm Biotechnol.,* February 2004, vol. 5 (1), 29-43 **[0176]**

- **BRUNSVIG PF ; AAMDAL S ; GJERTSEN MK ; KVALHEIM G ; MARKOWSKI-GRIMSRUD CJ ; SVE I ; DYRHAUG M ; TRACHSEL S ; MØLLER M ; ERIKSEN JA.** Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. *Cancer Immunol Immunother.,* 2006, vol. 55 (12), 1553-1564 **[0176]**
- **BURTON EC ; PRADOS MD.** Malignant gliomas. *Curr. Treat. Options. Oncol,* 2000, vol. 1, 459-468 **[0176]**
- Primary Brain Tumors in the United States. *Statistical Report.,* 2006 **[0176]**
- **CHEEVER MA ; CHEN W ; DISIS ML ; TAKAHASHI M ; PEACE DJ.** T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. *Ann N. Y. Acad. Sci.,* 1993, vol. 690, 101-112 **[0176]**
- **COLOMBETTI S ; BASSO V ; MUELLER DL ; MONDINO A.** Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. *J Immunol.,* 2006, vol. 176, 2730-2738 **[0176]**
- **CRESSWELL P.** Assembly, transport, and function of MHC class II molecules. *Annu. Rev. Immunol.,* 1994, vol. 12, 259-293 **[0176]**
- **DAZZI C ; CARIELLO A ; GIANNINI M ; DEL DM ; GIOVANIS P ; FIORENTINI G ; LEONI M ; ROSTI G ; TURCI D ; TIENGHI A.** A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study. *Anticancer Res.,* 2000, vol. 20, 515-518 **[0176]**
- **DENGJEL J ; NASTKE MD ; GOUTTEFANGEAS C ; GITSIOUDIS G ; SCHOOR O ; ALTENBEREND F ; MULLER M ; KRAMER B ; MISSIOU A ; SAUTER M.** Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. *Clin Cancer Res.,* 2006, vol. 12, 4163-4170 **[0176]**
- **DIX AR ; BROOKS WH ; ROSZMAN TL ; MORFORD LA.** Immune defects observed in patients with primary malignant brain tumors. *J Neuroimmunol.,* 1999, vol. 100, 216-232 **[0176]**
- **DUDLEY ME ; WUNDERLICH JR ; ROBBINS PF ; YANG JC ; HWU P ; SCHWARTZENTRUBER DJ ; TOPALIAN SL ; SHERRY R ; RESTIFO NP ; HUBICKI AM.** Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science,* vol. 298, 850-854 **[0176]**
- **DUDLEY ME ; WUNDERLICH JR ; YANG JC ; SHERRY RM ; TOPALIAN SL ; RESTIFO NP ; ROYAL RE ; KAMMULA U ; WHITE DE ; MAVROUKAKIS SA.** Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J. Clin. Oncol.,* 2005, vol. 23, 2346-2357 **[0176]**
- **DUPUIS M ; MURPHY TJ ; HIGGINS D ; UGOZZOLI M ; VAN NEST G ; OTT G ; MCDONALD DM.** Dendritic cells internalize vaccine adjuvant after intramuscular injection. *Cell Immunol.,* 1998, vol. 186 (1), 18-27 **[0176]**
- **FALK,K. ; ROTZSCHKE,O. ; STEVANOVIC,S. ; JUNG,G. ; RAMMENSEE,H.G.** Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature,* 1991, vol. 351, 290-296 **[0176]**
- **FONG L ; BROCKSTEDT D ; BENIKE C ; WU L ; ENGLEMAN EG.** Dendritic cells injected via different routes induce immunity in cancer patients. *J. Immunol.,* 2001, vol. 166, 4254-4259 **[0176]**
- **FONG L ; HOU Y ; RIVAS A ; BENIKE C ; YUEN A ; FISHER GA ; DAVIS MM ; ENGLEMAN EG.** Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. *Proc. Natl. Acad. Sci. U. S. A,* 2001, vol. 98, 8809-8814 **[0176]**
- **GABRILOVICH DI ; CUNNINGHAM HT ; CARBONE DP.** IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. *J Immunother Emphasis Tumor Immunol.,* 1996, 414-418 **[0176]**
- **GALON J ; COSTES A ; SANCHEZ-CABO F ; KIRILOVSKY A ; MLECNIK B ; LAGORCE-PAGES C ; TOSOLINI M ; CAMUS M ; BERGER A ; WIND P.** Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science,* 2006, vol. 313, 1960-1964 **[0176]**
- **GATTINONI L ; POWELL DJ, JR. ; ROSENBERG SA ; RESTIFO NP.** Adoptive immunotherapy for cancer: building on success. *Nat. Rev. Immunol.,* 2006, vol. 6, 383-393 **[0176]**
- **GEBBINK MF, VAN E, I ; HATEBOER G ; SUIJKERBUIJK R ; BEIJERSBERGEN RL ; GEURTS VAN KA ; MOOLENAAR WH.** Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. *FEBS Lett.,* 1991, vol. 290, 123-130 **[0176]**
- **GNJATIC S ; ATANACKOVIC D ; JAGER E ; MATSUO M ; SELVAKUMAR A ; ALTORKI NK ; MAKI RG ; DUPONT B ; RITTER G ; CHEN YT.** Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. *Proc Natl. Acad. Sci. U. S. A,* 2003, vol. 100, 8862-8867 **[0176]**
- **HAMMER J ; GALLAZZI F ; BONO E ; KARR RW ; GUENOT J ; VALSASNINI P ; NAGY ZA ; SINIGAGLIA F.** Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. *J Exp. Med,* 1995, vol. 181, 1847-1855 **[0176]**
- **HANADA K ; YEWDELL JW ; YANG JC.** Immune recognition of a human renal cancer antigen through post-translational protein splicing. *Nature,* 2004, vol. 427, 252-256 **[0176]**

- **HARROCH S ; FURTADO GC ; BRUECK W ; ROSENBLUTH J ; LAFAILLE J ; CHAO M ; BUXBAUM JD ; SCHLESSINGER J.** A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. *Nat. Genet.,* 2002, vol. 32, 411-414 **[0176]**
- **HEIMBERGER AB ; HUSSAIN SF ; ALDAPE K ; SAWAYA R ; ARCHER GA ; FRIEDMAN H ; REARDON D ; FRIEDMAN A ; BIGNER DD ; SAMPSON JH.** Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings,* 20 June 2006, vol. 24 (18S), 2529. 6-20, 2006 **[0176]**
- **HILL et al.** *J. Exp. Med.,* 1995, vol. 181, 2221-2228 **[0176]**
- **JEROME et al.** *J. Immunol.,* 1993, vol. 151, 1654-1662 **[0176]**
- **JOCHMUS et al.** *J. Gen. Virol.,* 1997, vol. 78, 1689-1695 **[0176]**
- **JUNG G ; LEDBETTER JA ; MULLER-EBERHARD HJ.** Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. *Proc Natl Acad Sci U S A,* 1987, vol. 84, 4611-4615 **[0176]**
- **KAPLAN R ; MORSE B ; HUEBNER K ; CROCE C ; HOWK R ; RAVERA M ; RICCA G ; JAYE M ; SCHLESSINGER J.** Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. *Proc Natl. Acad. Sci. U. S. A,* 1990, vol. 87, 7000-7004 **[0176]**
- **KARRE ; LJUNGGREN.** *J. Exp. Med.,* 1985, vol. 162, 1745 **[0176]**
- **KAWAKAMI et al.** *J. Immunol.,* 1992, vol. 148, 638-643 **[0176]**
- **KENNEDY RC ; SHEARER MH ; WATTS AM ; BRIGHT RK.** *Cancer Res.,* 2003, vol. 63, 1040-1045 **[0176]**
- **KOBAYASHI H ; OMIYA R ; RUIZ M ; HUARTE E ; SAROBE P ; LASARTE JJ ; HERRAIZ M ; SANGRO B ; PRIETO J ; BORRAS-CUESTA F.** Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. *Clin Cancer Res.,* 2002, vol. 8, 3219-3225 **[0176]**
- **ARTHUR M. KRIEG.** Therapeutic potential of Toll-like receptor 9 activation. *Nature Reviews, Drug Discovery,* June 2006, vol. 5, 471-484 **[0176]**
- **KRUEGER NX ; STREULI M ; SAITO H.** Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. *EMBO J,* 1990, vol. 9, 3241-3252 **[0176]**
- **LEMMEL C ; WEIK S ; EBERLE U ; DENGJEL J ; KRATT T ; BECKER HD ; RAMMENSEE HG ; STEVANOVIC S.** Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. *Nat. Biotechnol.,* 2004, vol. 22, 450-454 **[0176]**
- **LEVY JB ; CANOLL PD ; SILVENNOINEN O ; BARNEA G ; MORSE B ; HONEGGER AM ; HUANG JT ; CANNIZZARO LA ; PARK SH ; DRUCK T.** The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. *J Biol. Chem.,* 1993, vol. 268, 10573-10581 **[0176]**
- **LONGENECKER et al.** *Ann. NY Acad. Sci.,* 1993, vol. 690, 276-291 **[0176]**
- **LU et al.** *J. Org. Chem.,* 1981 **[0176]**
- **LU KV ; JONG KA ; KIM GY ; SINGH J ; DIA EQ ; YOSHIMOTO K ; WANG MY ; CLOUGHESY TF ; NELSON SF ; MISCHEL PS.** Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. *J Biol Chem.,* 2005, vol. 280, 26953-26964 **[0176]**
- **MACDONALD DR.** Temozolomide for recurrent high-grade glioma. *Semin. Oncol,* 2001, vol. 28, 3-12 **[0176]**
- **MACH B ; STEIMLE V ; MARTINEZ-SORIA E ; REITH W.** Regulation of MHC class II genes: lessons from a disease. *Annu. Rev. Immunol.,* 1996, vol. 14, 301-331 **[0176]**
- **A MAHDAVI ; BJ MONK.** Recent advances in human papillomavirus vaccines. *Curr Oncol Rep,* 2006, vol. 6, 465-472 **[0176]**
- **MALCHEREK G ; GNAU V ; STEVANOVIC S ; RAMMENSEE HG ; JUNG G ; MELMS A.** Analysis of allele-specific contact sites of natural HLA-DR17 ligands. *J Immunol.,* 1994, vol. 153, 1141-1149 **[0176]**
- **MANICI S ; STURNIOLO T ; IMRO MA ; HAMMER J ; SINIGAGLIA F ; NOPPEN C ; SPAGNOLI G ; MAZZI B ; BELLONE M ; DELLABONA P.** Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *J Exp. Med,* 1999, vol. 189, 871-876 **[0176]**
- **MORGAN RA ; DUDLEY ME ; WUNDERLICH JR ; HUGHES MS ; YANG JC ; SHERRY RM ; ROYAL RE ; TOPALIAN SL ; KAMMULA US ; RESTIFO NP.** Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. *Science,* 2006 **[0176]**
- **MULHOLLAND PJ ; FIEGLER H ; MAZZANTI C ; GORMAN P ; SASIENI P ; ADAMS J ; JONES TA ; BABBAGE JW ; VATCHEVA R ; ICHIMURA K.** Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. *Cell Cycle,* 2006, vol. 5, 783-791 **[0176]**
- **STRUBIN, M. ; MACH, B. ; LONG, E.O.** The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity. *EMBO J.,* 1984, vol. 3 (4), 869-872 **[0176]**

- **NAPOLITANO M ; KEIME-GUIBERT F ; MONJOUR A ; LAFITTE C ; AMERI A ; CORNU P ; BROET P ; DELATTRE JY.** Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. *J Neurooncol.,* 1999, vol. 45, 229-235 **[0176]**
- **NIEDER C ; GROSU AL ; MOLLS M.** A comparison of treatment results for recurrent malignant gliomas. *Cancer Treat. Rev.,* 2000, vol. 26, 397-409 **[0176]**
- **NOVELLINO L ; CASTELLI C ; PARMIANI G.** A listing of human tumor antigens recognized by T cells: March 2004 update. *Cancer Immunol. Immunother.,* 2005, vol. 54, 187-207 **[0176]**
- **PASCOLO S.** Vaccination with messenger. *RNA Methods Mol Med,* 2006, vol. 127, 23-40 **[0176]**
- **PEOPLES et al.** *Proc. Natl. Acad. Sci. USA,* 1995, vol. 92, 432-436 **[0176]**
- **PEREZ-PINERA P ; GARCIA-SUAREZ O ; MENENDEZ-RODRIGUEZ P ; MORTIMER J ; CHANG Y ; ASTUDILLO A ; DEUEL TF.** The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. *Biochem. Biophys. Res. Commun.,* 2007, vol. 362, 5-10 **[0176]**
- **PLEBANSKI et al.** *Eur. J. Immunol.,* 1995, vol. 25, 1783-1787 **[0176]**
- **PORTA et al.** *Virology,* 1994, vol. 202, 449-955 **[0176]**
- **PRADOS MD ; LEVIN V.** Biology and treatment of malignant glioma. *Semin. Oncol,* 2000, vol. 27, 1-10 **[0176]**
- **QIN Z ; BLANKENSTEIN T.** CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. *Immunity,* 2000, vol. 12, 677-686 **[0176]**
- **QIN Z ; SCHWARTZKOPFF J ; PRADERA F ; KAMMERTOENS T ; SELIGER B ; PIRCHER H ; BLANKENSTEIN T.** A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. *Cancer Res.,* 2003, vol. 63, 4095-4100 **[0176]**
- **RAMMENSEE HG ; BACHMANN J ; EMMERICH NP ; BACHOR OA ; STEVANOVIC S.** SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics,* 1999, vol. 50, 213-219 **[0176]**
- **RAMMENSEE,H.G. ; BACHMANN,J. ; STEVANOVIC,S.** MHC Ligands and Peptide Motifs. Springer-Verlag, 1997 **[0176]**
- **RINI BI ; WEINBERG V ; FONG L ; CONRY S ; HERSHBERG RM ; SMALL EJ.** Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. *Cancer,* 2006, vol. 107 (1), 67-74 **[0176]**
- **ROSENBERG SA ; LOTZE MT ; MUUL LM ; CHANG AE ; AVIS FP ; LEITMAN S ; LINEHAN WM ; ROBERTSON CN ; LEE RE ; RUBIN JT.** A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N. Engl. J. Med.,* 1987, vol. 316, 889-897 **[0176]**
- **ROSENBERG SA ; PACKARD BS ; AEBERSOLD PM ; SOLOMON D ; TOPALIAN SL ; TOY ST ; SIMON P ; LOTZE MT ; YANG JC ; SEIPP CA.** Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N. Engl. J Med,* 1988, vol. 319, 1676-1680 **[0176]**
- **ROTH W ; WELLER M.** Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. *Cell Mol. Life Sci.,* 1999, vol. 56, 481-506 **[0176]**
- **SABLOTZKI A ; EBEL H ; MUHLING J ; DEHNE MG ; NOPENS H ; GIESSELMANN H ; HEMPELMANN G.** Dysregulation of immune response following neurosurgical operations. *Acta Anaesthesiol. Scand.,* 2000, vol. 44, 82-87 **[0176]**
- **SAIKI et al.** *Science,* 1988, vol. 239, 487-491 **[0176]**
- **SMALL EJ ; SCHELLHAMMER PF ; HIGANO CS ; REDFERN CH ; NEMUNAITIS JJ ; VALONE FH ; VERJEE SS ; JONES LA ; HERSHBERG RM.** Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol.,* 2006, vol. 24 (19), 3089-3094 **[0176]**
- **SCHUBERT U ; ANTON LC ; GIBBS J ; NORBURY CC ; YEWDELL JW ; BENNINK JR.** Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. *Nature,* 2000, vol. 404, 770-774 **[0176]**
- **SEEGER,F.H. et al.** The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. *Immunogenetics,* 1999, vol. 49, 571-576 **[0176]**
- **SHEDLOCK DJ ; SHEN H.** Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science,* 2003, vol. 300, 337-339 **[0176]**
- **SINGH-JASUJA H ; EMMERICH NP ; RAMMENSEE HG.** The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. *Cancer Immunol. Immunother.,* 2004, vol. 53, 187-195 **[0176]**
- **M. STAEHLER ; A. STENZL ; P. Y. DIETRICH ; T. EISEN ; A. HAFERKAMP ; J. BECK ; A. MAYER ; S. WALTER ; H. SINGH ; J. FRISCH.** An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901. *ASCO meeting 2007,* 2008 **[0176]**

- **R. STAN ; JD WOLCHOK ; AD COHEN.** DNA vaccines against cancer. *Hematol Oncol Clin North Am,* 2006, vol. 3, 613-636 **[0176]**
- **SUN JC ; BEVAN MJ.** Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science,* 2003, vol. 300, 339-342 **[0176]**
- **SYLVESTER-HVID C ; KRISTENSEN N ; BLICHER T ; FERRE H ; LAUEMOLLER SL ; WOLF XA ; LAMBERTH K ; NISSEN MH ; PEDERSEN LO ; BUUS S.** Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. *Tissue Antigens,* 2002, vol. 59, 251-258 **[0176]**
- **TOMPKINS SM ; ROTA PA ; MOORE JC ; JENSEN PE.** A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. *J Immunol. Methods,* 1993, vol. 163, 209-216 **[0176]**
- **VAN DER BRUGGEN P ; TRAVERSARI C ; CHOMEZ P ; LURQUIN C ; DE PE ; VAN DEN EB ; KNUTH A ; BOON T.** A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science,* 1991, vol. 254, 1643-1647 **[0176]**
- **VIGNERON N ; STROOBANT V ; CHAPIRO J ; OOMS A ; DEGIOVANNI G ; MOREL S ; VAN DER BP ; BOON T ; VAN DEN EYNDE BJ.** An antigenic peptide produced by peptide splicing in the proteasome. *Science,* 2004, vol. 304, 587-590 **[0176]**
- **VOGT AB ; KROPSHOFER H ; KALBACHER H ; KALBUS M ; RAMMENSEE HG ; COLIGAN JE ; MARTIN R.** Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. *J Immunol.,* 1994, vol. 153, 1665-1673 **[0176]**
- **WALTER S ; HERRGEN L ; SCHOOR O ; JUNG G ; WERNET D ; BUHRING HJ ; RAMMENSEE HG ; STEVANOVIC S.** Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. *J. Immunol.,* 2003, vol. 171, 4974-4978 **[0176]**
- **WANG JC ; LIVINGSTONE AM.** Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. *J Immunol.,* 2003, vol. 171, 6339-6343 **[0176]**
- **WANG V ; DAVIS DA ; HAQUE M ; HUANG LE ; YARCHOAN R.** Differential gene up-regulation by hypoxia-inducible factor-lalpha and hypoxia-inducible factor-2alpha in HEK293T cells. *Cancer Res.,* 2005, vol. 65, 3299-3306 **[0176]**
- **WEINSCHENK T ; GOUTTEFANGEAS C ; SCHIRLE M ; OBERMAYR F ; WALTER S ; SCHOOR O ; KUREK R ; LOESER W ; BICHLER KH ; WERNET D.** Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res.,* 2002, vol. 62, 5818-5827 **[0176]**
- **WU CW ; !LOST DATA ; LI AF ; CHI CW ; LIN WC.** Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. *Cancer Lett.,* 2006, vol. 242, 95-103 **[0176]**
- **YEE C ; THOMPSON JA ; BYRD D ; RIDDELL SR ; ROCHE P ; CELIS E ; GREENBERG PD.** Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. *Proc. Natl. Acad. Sci. U. S. A,* 2002, vol. 99, 16168-16173 **[0176]**
- **ZAREMBA S ; BARZAGA E ; ZHU M ; SOARES N ; TSANG KY ; SCHLOM J.** Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. *Cancer Res.,* 1997, vol. 57, 4570-4577 **[0176]**
- **ZEH HJ, III ; PERRY-LALLEY D ; DUDLEY ME ; ROSENBERG SA ; YANG JC.** High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. *J Immunol.,* 1999, vol. 162, 989-994 **[0176]**

FB 19941
Immatics biotechnologies GmbH
EP 08 005 889.4

Újszerű immunterápia neuronális és agydaganatok ellen

SZABADALMI IGÉNYPONTOK

1. A SEQ ID No. 1 szerinti aminosav-szekvenciából álló peptid.

2. Az 1. igénypont szerinti peptid, amelyben az említett peptid a HLA-DR antigén asszociált invariáns lánc (Ii) N-terminális aminosavait tartalmazó fúziós protein részét képezi.

3. Az 1. vagy a 2. igénypont szerinti peptidet kódoló nukleinsav.

4. A 3. igénypont szerinti nukleinsavat expresszáló expressziós vektor.

5. Az 1. vagy a 2. igénypont szerinti peptid, a 3. igénypont szerinti nukleinsav vagy a 4. igénypont szerinti expressziós vektor, gyógyászatban történő alkalmazásra.

6. A 3. igénypont szerinti nukleinsavat vagy a 4. igénypont szerinti expressziós vektort tartalmazó izolált gazdasejt, amely nem humán embrionális ősejt, ahol az említett gazdasejt előnyösen egy antigénprezentáló sejt, különösen egy dendritikus sejt.

7. Az 1. vagy a 2 igénypont szerinti peptid előállítására szolgáló módszer, amely a 3. igénypont szerinti nukleinsavat vagy a 4. igénypont szerinti expressziós vektort expresszáló, a 6. igénypont szerinti gazdasejt tenyésztéséből, és a peptidnek a gazdasejtből vagy a tenyészközegből történő izolálásából áll.

8. Egy *in vitro* módszer aktivált citotoxikus T-limfociták (CTL) előállítására, melynek során a CTL-t *in vitro* egy alkalmas antigénprezentáló sejt felületén expresszált humán I. osztályú, antigénnel feltöltött MHC molekulákkal vagy az antigénprezentáló sejtet utánzó mesterséges konstrukttal hoznak érintkezésbe annyi ideig, amennyi elegendő az említett CTL antigén-specifikus aktivációjához, amelyben az említett antigén az 1. igénypont szerinti peptid.

9. Az 1. vagy a 2 igénypont szerinti peptid, a 3. igénypont szerinti nukleinsav, a 4. igénypont szerinti expressziós vektor vagy a 6. igénypont szerinti sejt, rákbetegség kezelésében történő alkalmazásra.

10. Az 1. vagy 2. igénypont szerinti peptid, a 3. igénypont szerinti nukleinsav, a 4. igénypont szerinti expressziós vektor vagy a 6. igénypont szerinti sejt, rákbetegség elleni gyógyszer gyártásában történő alkalmazásra.

11. Az 1. vagy a 2. igénypont szerinti peptid, a 3. igénypont szerinti nukleinsav, a 4. igénypont szerinti expressziós vektor vagy a 6. igénypont szerinti sejt, a 10. igénypont szerinti alkalmazásra, ahol az említett gyógyszer egy vakcina.

12. Az 1. vagy a 2. igénypont szerinti peptid, a 3. igénypont szerinti nukleinsav, a 4. igénypont szerinti expressziós vektor, vagy a 6. igénypont szerinti sejt, a 10. vagy a 11. igénypont szerinti alkalmazásra, ahol az említett rákbetegség a következő csoportból választható: astrocytoma, pilocytas astrocytoma, dysembryoplasticus neuroepithelialis tumor, oligodendrogliomák, ependymoma, glioblastoma multiforme, vegyes gliomák, oligoastrocytomák, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomák, gangliocytoma, centralis gangliocytoma, primitív neuroectodermalis tumorok (PNET), medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma, a tobozmirigy parenchyma daganatai (pl. pineocytoma, pineoblastoma), ependymasejt daganatok, bizonytalan eredetü neuroepithelialis daganatok, gliomatosis cerebri, astroblastoma vagy glioblastoma.